EudraCT: 2020 -004094 -52 Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
A PHASE 3 RANDOMIZED , DOUBLE -BLIND, PLAC EBO -
CONTROLLED STUDY ASS ESSING THE EFFICACY OF  
ANTI -BET V 1 MONOCLONAL ANTIBODIE S TO REDUCE 
SYMPTOMS OF SEASONAL  ALLERGIC RHINITIS  
Compound : REGN5713 -5714 -5715  
Clinical Phase:  3 
Protocol Number:  R5713 -5714 -5715 -ALG -2001  
Protocol Version:  R5713 -5714 -5715 -ALG -2001 Original  
Date of Issue:   See appended electronic signature [CONTACT_550091]/Study Director:  
Regeneron Pharmaceuticals, Inc.  
[ADDRESS_721344]  
Tarrytown, NY [ZIP_CODE]  
VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00[STUDY_ID_REMOVED]

Clinical Study Protocol   R5713 -[ADDRESS_721345]  Aspartate aminotransferase  
AUC  Area under the curve  
BAT  Basophil activation tests  
BUN  Blood urea nitrogen  
COVID -19 Coronavirus Disease 2019  
CRF  Case report form (electronic or paper)  
CRO  Contract research organization  
CSMS  Combined symptom and medication score  
CSR  Clinical study report  
CTFG  Clinical Trial Facilitation Group  
DMS  Daily medication score  
EC Ethics Committee  
ECG  Electrocardiogram  
EDC  Electronic data capture  
EMA  European Medicines Agency  
FAS Full analysis set  
FBR  Future biomedical research  
FDA  Food and Drug Administration  
FIH First in human  
FSH Follicle stimulating hormone  
GCP  Good Clinical Practice  
ICF Informed consent form  
ICH International Council for Harmonisation  
Ig Immunoglobulin  
IRB Institutional Review Board  
IRT Interactive response technology  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 3 
CONFIDENTIAL  IUD Intrauterine device  
IUS Intrauterine hormone -releasing system  
IV Intravenous  
IVRS  Interactive voice response system  
IWRS  Interactive web response system  
LAM  Lactational amenorrhea method  
mAb  Monoclonal antibody  
NAb  Neutralizing antibody  
OAS  Oral allergy syndrome  
PBMC  Peripheral blood mononuclear cells  
PCA  Percutaneous anaphylaxis  
PCSV  Potentially clinically significant value  
PD Pharmacodynamic  
PFAS  Pollen food allergy syndrome  
PFASQ  Pollen food allergy sy mptom questionnaire  
PGI-S Patient Global Impression of Severity  
PK Pharmacokinetic  
POC  Proof of concept  
RBC  Red blood cell  
RBQM  Risk-Based Quality Monitoring  
Regeneron  Regeneron Pharmaceuticals, Inc.  
RQLQ (S)  Standardized Rhinoconjunctivitis Quality  of Life Questionnaire  
RSOC  Regeneron Safety Oversight Committee  
RSV  Respi[INVESTIGATOR_550014] -CoV -2 Severe acute respi[INVESTIGATOR_6507]  2 
SAS Statistical Analysis System  
SC Subcutaneous  
SCIT  Subcutaneous immunotherapy  
sIgE Allergen -specific IgE  
SIT Specific immunotherapy  
SLIT  Sublingual immunotherapy  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721346]  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
TEAE  Treatment -emergent adverse event  
TNSS  Total nasal symptom score  
TOSS  Total ocular symptom score  
TSS Total symptom score  
WAO  World Allergy Organization  
WBC  White blood cell  
WOCBP  Women of childbearing potential  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721347] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .................. 2 
CLINICAL STUDY PROTO COL SYNOPSIS ................................ ................................ ............. 11 
1. INTRODUCTION  ................................ ................................ ................................ ......16 
1.1. Allergic Disease, Birch Allergy, and Allergen -Specific Immunotherapy  .................. 16 
1.2. Monoclonal Antibodies for the Treatment of Allergic Diseases  ................................ 17 
1.3. REGN5713, REGN5714,  and REGN5715: Fully Human Monoclonal 
Antibodies Against Bet v 1  ................................ ................................ ......................... 18 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 19 
2.1. Primary Objective  ................................ ................................ ................................ .......19 
2.2. Secondary Objectives  ................................ ................................ ................................ .20 
2.3. Exploratory Objectives  ................................ ................................ ............................... 20 
3. HYPOTHESIS AND RATIO NALE  ................................ ................................ .......... 21 
3.1. Hypothesis  ................................ ................................ ................................ .................. 21 
3.2. Rationale  ................................ ................................ ................................ ..................... 21 
3.2.1.  Rationale f or Study Design  ................................ ................................ ......................... 21 
3.2.2.  Rationale for Dose Selection  ................................ ................................ ...................... 23 
3.2.3.  Rationale for the Selected Anti -Bet v 1 Monoclonal Antibody Cocktail  ................... 24 
3.3. Risk-Benefit  ................................ ................................ ................................ ................ 24 
4. ENDPOINTS  ................................ ................................ ................................ .............. 25 
4.1. Primary Endpoint  ................................ ................................ ................................ ........ 25 
4.2. Seconda ry Endpoints  ................................ ................................ ................................ ..25 
4.3. Exploratory Endpoints  ................................ ................................ ................................ 26 
5. STUDY VARIABLES ................................ ................................ ................................ 26 
5.1. Demographic and Baseline Characteristics  ................................ ................................ 26 
5.2. Efficacy Variables  ................................ ................................ ................................ ......26 
5.3. Safety Variables  ................................ ................................ ................................ .......... 27 
5.4. Pharmac okinetic Variables  ................................ ................................ ......................... 27 
5.5. Immunogenicity Variables  ................................ ................................ .......................... 27 
5.6. Pharmacodynamic and Other Biomarker Variables  ................................ ................... 27 
5.7. Other Variables  ................................ ................................ ................................ ........... 27 
6. STUDY DES IGN ................................ ................................ ................................ .......27 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 6 
CONFIDENTIAL  6.1. Study Description and Duration  ................................ ................................ ................. 27 
6.1.1.  Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .28 
6.1.2.  End of Study Definition  ................................ ................................ .............................. 28 
6.2. Planned Interim Analysis  ................................ ................................ ............................ 28 
6.3. Study Committees  ................................ ................................ ................................ .......29 
6.3.1.  Safet y Monitoring Team  ................................ ................................ ............................. 29 
6.3.2.  Independent Data Monitoring Committee  ................................ ................................ ..29 
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F SUBJECTS  .............. 29 
7.1. Number of Subjects Planned  ................................ ................................ ...................... 29 
7.2. Study Population  ................................ ................................ ................................ ......... 29 
7.2.1.  Inclusion Criteria  ................................ ................................ ................................ ........ 30 
7.2.2.  Exclusion Criteria  ................................ ................................ ................................ .......30 
7.3. Premature Withdrawal from the Study  ................................ ................................ .......33 
7.4. Replacement of Subjects  ................................ ................................ ............................. 33 
8. STUDY TREATMENTS ................................ ................................ ............................ 33 
8.1. Investiga tional and Reference Treatments  ................................ ................................ ..33 
8.2. Rescue Treatments  ................................ ................................ ................................ ......33 
8.3. Dose Modification and Study Treatment Discontinuation Rules  ............................... 34 
8.4. Management of Acute Reactions  ................................ ................................ ................ 34 
8.4.1.  Acute Injection Reactions  ................................ ................................ ........................... 34 
[IP_ADDRESS].  Systemic Injection Reactions  ................................ ................................ ...................... 34 
[IP_ADDRESS].  Local Injection Site Reactions  ................................ ................................ .................... 34 
8.5. Method of Treatment Assignment  ................................ ................................ .............. 35 
8.6. Blinding  ................................ ................................ ................................ ...................... 35 
8.7. Emergency Unblinding  ................................ ................................ ............................... 35 
8.8. Treatment Logistics and Accountability  ................................ ................................ .....36 
8.8.1.  Packaging, Labeling, and Storage  ................................ ................................ .............. 36 
8.8.2.  Supply and Disposition of Treatments  ................................ ................................ .......36 
8.8.3.  Treatment Accountability  ................................ ................................ ........................... 36 
8.8.4. Treatment Compliance  ................................ ................................ ................................ 37 
8.9. Concomitant Medications  ................................ ................................ ........................... 37 
8.9.1.  Prohibited Medications  ................................ ................................ ............................... 37 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 7 
CONFIDENTIAL  8.9.2.  Permitted Medications  ................................ ................................ ................................ 38 
9. STUDY SCHEDULE OF EVE NTS AND PROCEDURES  ................................ ......38 
9.1. Schedule of Events  ................................ ................................ ................................ .....38 
9.1.1.  Footnotes for the Schedule of Events Table  ................................ ............................... 41 
9.1.2.  Early Termination Visit  ................................ ................................ .............................. 42 
9.1.3.  Unscheduled Visits  ................................ ................................ ................................ .....42 
9.2. Study Procedures  ................................ ................................ ................................ ........ 42 
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....[ADDRESS_721348] Regional Skin Prick Tests  ................................ ............ 43 
9.2.4.  Efficacy Procedures  ................................ ................................ ................................ ....43 
9.2.4. 1. Total Nasal Symptom Score  ................................ ................................ ....................... 43 
[IP_ADDRESS].  Total Ocular Symptom Score  ................................ ................................ ..................... 43 
[IP_ADDRESS].  Total Symptom Score  ................................ ................................ ................................ .43 
[IP_ADDRESS].  Daily Medication Score  ................................ ................................ .............................. 43 
[IP_ADDRESS].  Combined Symptom and Medication Score  ................................ ............................... 43 
[IP_ADDRESS].  Asthma Control Questionnaire  ................................ ................................ ................... 44 
[IP_ADDRESS].  Standardized Rhinoconjunctivitis Quality of Life Questionnaire  .............................. 44 
[IP_ADDRESS].  Pollen Food Allergy Symptom Questionnaire  ................................ ............................ 44 
[IP_ADDRESS].  Patient Global Impression of Severity  ................................ ................................ ........ 44 
9.2.5.  Safety Procedures  ................................ ................................ ................................ .......44 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 44 
[IP_ADDRESS].  Physical Examination  ................................ ................................ ................................ .44 
[IP_ADDRESS].  Body Weight  ................................ ................................ ................................ ............... 45 
[IP_ADDRESS].  Spi[INVESTIGATOR_038]  ................................ ................................ ................................ .................. 45 
9.2.6.  Electro cardiogram  ................................ ................................ ................................ .......45 
9.2.7.  Laboratory Testing  ................................ ................................ ................................ ......45 
[IP_ADDRESS].  Hematology, Blood Chemistry, Pregnancy Test, and Urinalysis  ............................... 45 
[IP_ADDRESS].  Serum Antibodies  ................................ ................................ ................................ .......46 
9.2.8.  Drug Concentration and Measurements  ................................ ................................ .....47 
9.2.9.  Immunogenicity Measurements and Samples  ................................ ............................ 47 
9.2.10.  Pharmacodynamic and Exploratory Biomarker Procedures  ................................ .......47 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 8 
CONFIDENTIAL  [IP_ADDRESS].  Exploratory Biomarker Research  ................................ ................................ ............... 47 
9.2.11.  Future Biomedical Research (Optional)  ................................ ................................ .....48 
9.2.12.  Pharmacogenomic Analysis (Optional)  ................................ ................................ ......[ADDRESS_721349] Disposition  ................................ ................................ ................................ .....56 
11.4.2.  Demography and Baseline Characteristics  ................................ ................................ .56 
11.4.3.  Efficacy Analyses  ................................ ................................ ................................ .......56 
[IP_ADDRESS].  Primary Efficacy Analysis  ................................ ................................ .......................... 56 
[IP_ADDRESS].  Secondary Efficacy Analysis  ................................ ................................ ...................... 57 
[IP_ADDRESS].  Exploratory Efficacy Analysis  ................................ ................................ .................... 57 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 9 
CONFIDENTIAL  11.4.4.  Control of Multiplicity  ................................ ................................ ................................ 57 
11.4.5.  Safety Analysis  ................................ ................................ ................................ ........... 58 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 58 
[IP_ADDRESS].  Other Safety  ................................ ................................ ................................ ................ 58 
[IP_ADDRESS].  Treatment Exposure  ................................ ................................ ................................ ....59 
[IP_ADDRESS].  Treatment Compliance  ................................ ................................ ................................ 59 
11.4.6.  Pharmacokinetics  ................................ ................................ ................................ ........ 59 
[IP_ADDRESS] . Analysis of Drug Concentration Data  ................................ ................................ ......... [ADDRESS_721350] and Ethics Committee  ................................ .................... 65 
13.5.  Clinical Study Data Transparency  ................................ ................................ .............. 65 
14. PROTOCOL AMENDMENTS  ................................ ................................ .................. 65 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 10 
CONFIDENTIAL  15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE -OUT OF A 
SITE  ................................ ................................ ................................ ............................ 65 
15.1.  Premature Termination of the Study  ................................ ................................ ........... 65 
15.2.  Close -out of a Site  ................................ ................................ ................................ ......66 
16. CONFIDENTIALITY  ................................ ................................ ................................ 66 
17. FINANCING AND INSURANCE  ................................ ................................ ............. 66 
18. PUBLICATION POLICY  ................................ ................................ .......................... 66 
19. REFERENCES  ................................ ................................ ................................ ........... 67 
20. INVESTIGATOR’S AGREE MENT  ................................ ................................ .......... 73 
SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS ................................ ..................... [ADDRESS_721351] OF TABLES  
Table  1: Schedule of Events  ................................ ................................ ................................ .....[ADDRESS_721352] OF FIGURES  
Figure  1: Study Flow Diagram  ................................ ................................ ................................ ...28 
 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 11 
CONFIDENTIAL  CLINICAL STUDY PROTO COL SYNOPSIS  
Title  A Phase 3 Randomized, Double -Blind, Placebo -Controlled Study Assessing the Efficacy 
of Anti -Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seaso nal Allergic Rhinitis  
Site Locations  
Principal 
Investigator  [INVESTIGATOR_101792] 50 sites in North America and Europe  
To be determined  
Objectives  Primary Objectives  
The primary objective is to assess the reduction of allergic symptoms as measured by 
[CONTACT_550035] (CSMS) during birch pollen season after a single 
dose of REGN5713 -5714 -5715 versus placebo.  
Secondary Objectives  
The secondary objec tives are:  
• To assess the reduction of allergic symptoms and use of allergy -relieving 
medications after a single dose of REGN5713 -5714 -5715 versus placebo, as 
measured by [CONTACT_550036] (TSS), total nasal symptom score (TNSS), 
total ocular symptom score (TOSS), and daily medication score (DMS)  
• To evaluate the safety and tolerability of REGN5713 -5714 -5715, including the 
incidence of hypersensitivity reactions and local injection site reactions  
• To evaluate the reduction in early allergic response to b irch allergen after a 
single dose of REGN5713 -[ADDRESS_721353] (SPT) mean wheal diameter  
• To determine systemic exposure of total antibody (ie, free and antigen -bound) 
in the form of concentration of REGN5713, REGN571 4, and REGN5715 in 
serum  
• To assess the immunogenicity to REGN5713, REGN5714, and REGN5715 in 
subjects after a single dose of REGN5713 -5714 -5715  
• To evaluate “well days”  
Note: “Well days” are defined as days when the TSS is ≤2 without the use of 
anti-allergy rescue medications.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 12 
CONFIDENTIAL   Exploratory Objectives  
The exploratory objectives are:  
• To assess asthma control as measured by [CONTACT_550037] 
(ACQ -5) 
• To assess quality of life as measured by [CONTACT_550038] (RQLQ [S])  
• To evaluate the reduction in early allergic response to birch homologous 
allergens (alder and oak) as measured by [CONTACT_550039]  
• To assess the relationship between allergy sensitization status to Bet v 1 or birch 
pollen at screening (as measured by [CONTACT_550040] -IgE [sIgE]) and 
clinical response to REGN5713 -5714 -5715 treatment  
• To assess serum sIgE levels against Bet v 1 a nd birch pollen during birch pollen 
season to evaluate the relationship between the response to REGN5713 -5714 -
5715 and change in sIgE levels in -season  
• To assess the inhibitory effect of REGN5713 -5714 -5715 on the binding of 
endogenous serum IgE to birch al lergen in an in vitro assay; to assess whether 
the degree of inhibition correlates with clinical improvement  
• To assess sIgE levels against other allergens (eg, Bet v 2, alder and oak) at 
screening and to evaluate the relationship between response to REGN5 713-
5714 -5715 and poly -allergic status  
• To assess additional subclasses of serum antibodies (eg, total IgG and IgG4 
against birch pollen and Bet v 1) to evaluate the relationship between 
endogenous anti -Bet v 1 antibodies and response to REGN5713 -5714 -5715  
• To assess the reduction in pollen food allergy syndrome (PFAS) and related 
symptoms as measured by [CONTACT_550041] (PFASQ)  
• To assess patient rating of severity of seasonal allergy symptoms as measured 
by [CONTACT_550042] (PGI -S) 
Study Design  This is a phase 3 multi -center, randomized, double -blind, placebo -controlled, parallel 
group study to assess the efficacy of anti -Bet v 1 monoclonal antibodies (mAbs; 
REGN5713 -5714 -5715) to reduce allergic rhinitis and co njunctivitis symptoms and the 
use of rescue medications during birch pollen season. Efficacy will be evaluated by 
[CONTACT_550043] n, after a single SC dose of 
REGN5713 -5714 -5715 or placebo.  
The incidence and severity of treatment -emergent adverse events (TEAEs), including 
hypersensitivity reactions and local injection site reactions, will be assessed. Total 
concentration in serum an d immunogenicity of REGN5713, REGN5714, and REGN5715 
will also be measured.  
Study Duration  The total study duration is approximately 28 weeks including screening, dependent on the 
start and end times of the local birch pollen season. The length of birch pollen season will 
vary based on geography.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721354] to follow -up (ie, the study subject can no longer be 
contacte d by [CONTACT_093]).  
Population  Approximately 300 generally healthy adult male and female subjects with birch allergy 
will be enrolled. Other inclusion and exclusion criteria apply.  
Study Drug and 
Placebo  
Dose/Route/Schedul
e: • REGN5713 -5714 -5715 900 mg  (300 mg per mAb), single SC dose  
• Matching placebo that replaces REGN5713 -5714 -5715, single SC dose  
Endpoints  Primary Endpoint  
The primary endpoint is the daily CSMS, averaged over the duration of the birch pollen 
season, in subjects who receive a single dose of REGN5713 -5714 -5715 versus placebo.  
Secondary Endpoints  
The secondary endpoints are:  
• TSS, TNSS, and TOSS, averaged over the duration of the birch pollen season, 
in subjects who receive a single dose of REGN5713 -5714 -5715 versus placebo  
• DMS, average d over the duration of the birch pollen season, in subjects who 
receive a single dose of REGN5713 -5714 -5715 versus placebo  
• Incidence of TEAEs and serious TEAEs throughout the study  
• Change and percent change from baseline to the end of study in birch SPT mean 
wheal diameter in subjects who receive a single dose of REGN5713 -5714 -5715 
versus placebo  
• Total REGN5713, REGN5714, and REGN5715 concentration in serum over 
the study duration  
• Incidence of treatment emergent anti -drug antibodies (ADAs) to REGN5713, 
REGN5714, or REGN 5715 throughout the study  
• The number of “well days” in each of the treatment groups, where the “well 
days” are defined as days when rescue medication is not utilized and the TSS 
is ≤2/18  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 14 
CONFIDENTIAL   Exploratory Endpoints  
The exploratory endpoints are : 
• ACQ -5, averaged over the duration of the birch pollen season, for 
REGN5713 -5714 -5715 versus placebo  
• RQLQ (S), averaged over the duration of the birch pollen season, for 
REGN5713 -5714 -5715 versus placebo  
• Change and percent change from baseline to the end of study in SPT mean 
wheal diameter for birch homologous/cross -reactive allergens in 
REGN5713 -5714 -5715 versus placebo  
• Baseline allergen -specific IgE levels and correlation with average CSMS, TSS, 
TNSS, TOSS, DMS during birch pollen season  
• Change and percent change from baseline to the peak of birch pollen season in 
allergen -specific IgE  
• Change in inhibitory effect on serum IgE to birch allergen  
• Number of baseline sensitizations to other allergens (poly/mono -sensitization 
status, based on allergen -specific IgE levels) and correlation with CSMS, TSS, 
TNSS, TOSS, and DMS, averaged over the duration of the birch pollen season  
• Baseline serum antibody levels and correlation with CSMS, TSS, TNSS, TOSS, 
and DMS, averaged over the duration of the birch pollen season  
• To assess the reduction in PFAS and related symptoms, as measured by 
[CONTACT_550044], from baseline to end of study  
• To assess patient rating of severity of seasonal allergy symptoms, as measured 
by [CONTACT_380440] -S, from baseline to end of study  
Procedures and 
Assessm ents The following procedures will be performed to determine study eligibility and characterize 
the baseline population:  
• Skin prick test (SPT) for birch and standard regional allergens  
• Serum allergen -specific IgE (sIgE) tests for birch tree pollen and Bet v 1  
• Serum sIgE tests for concomitant and homologous allergens  
• Medical history, demographics, weight, height, vital signs, physical 
examination, electrocardiogram (ECG), spi[INVESTIGATOR_038], hem atology, and blood 
chemistry  
Efficacy assessments will include TNSS, TOSS, DMS, ACQ -5, RQLQ (S), PFASQ, and 
PGI-S. 
Safety assessments will include monitoring laboratory tests (hematology, blood chemistry, 
pregnancy tests), weight, vital signs, physical exa mination, adverse events (AEs), 
concomitant medications, and spi[INVESTIGATOR_038].  
Samples will also be collected for PK, ADA, and exploratory research.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721355] differences between REGN5713 -5714-5715 and placebo 
on the primary endpoint of the average CSMS during birch pollen season. A sample size 
of 150 enrolled subjects per arm gives 90% power to detect a mean difference in average 
CSMS of 1.9 (30% reduction from placebo) in REGN5713 -5714 -5715 (mean 
CSMS  = 4.4) and placebo (mean CSMS = 6.3), assuming a common standard deviation in 
CSMS of 4.5. The minimum significant difference in CSMS is 1.14, or approximately an 
18% reduction from placebo. This sample size calculation assumes a 20% drop out ra te 
(30 subjects per arm) and a two -sample t -test with two -sided alpha of 0.05. Estimates of 
mean and variability of the CSMS are based on pooled estimates across several field 
studies for grass immunotherapy, and a 30% treatment effect relative to placebo is in line 
with what was observed in the phase 1b POC study for REGN5713 -[ADDRESS_721356] with symptom and medical 
score (SMS) will be included. The CSMS will be calculated on all available d ata during 
the birch pollen season. The primary analysis will be based on the available values of daily 
symptom score and daily medication score to calculate the average CSMS and no 
imputation will be needed for the primary endpoint during the birch pollen  season.  
The average CSMS will be calculated based on daily symptom score (TNSS and TOSS, 
max of 18/day) and daily medication score (max of 20/day) recorded over the duration of 
the birch pollen season. The start and end of the birch pollen season will be  defined for 
each site based on the local birch pollen counts. Only days with observed data (including 
any available data of daily entries prior to subject discontinuation) will be included in the 
calculation of the average CSMS.  
 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721357] costs (eg, medications and physician visits) and indirect costs 
(eg, los s of productivity/working day) (Vandenplas, 2018 ). The current prevalence of allergic 
rhinitis is 10% to 30% in adults worldwide, and up to 37% in children in some Western countries 
(Pawankar, 2011 ), affecting approximately 500 million people worldwide (Brozek, 2017 ). Allergic 
rhinitis is characterized by 1 or more symptoms including sneezing, itching, nasal congestion, and 
rhinorrhea on consecutive days. Allergic conjunctivitis is also commonly coexistent, occurring in 
approximately 65% of people with the nasal symptoms of allergic rhinitis (Navarro, 2009 ) 
(Rosario, 2011 ). Symptoms of fatigue, malaise, irritability, and neurocognitive deficits are 
prevalent (Wallace, 2008 ). Perennial allergic rhinitis is typi[INVESTIGATOR_550015] (eg, dust mites, mold, and animal dander), while seasonal allergic rhinitis is most often 
due to  sensitization to pollen allergens (eg, trees, grass, and weeds). In addition, asthma prevalence 
is 10% to 40% in those with allergic rhinitis (Shaaban, 2008 ), and allergic rhinitis is a risk factor 
for the development of asthma (Guerra, 2002 ) (Leynaert, 2000 ).  
In Europe and North America, clinically relevant sensitization to birch tree pollen affects 
approximately 8% to 16% of the overall population (Biedermann, 2019a ) (Chan -Yeung, 2010 ) 
(Salo, 2014 ) and approximately 20% to 30% of the popu lation with allergic rhinitis 
(Burbach,  2009 ) (Galant, 1998 ) (Lin, 2002 ) (Pablos, 2016 ) (Sierra -Heredia , 2018 ). Birch pollen 
contains a mix of allergenic and non -allergenic proteins, and Bet v [ADDRESS_721358] abundant 
allergenic pollen protein (Erler, 2011 ) (Schenk, 2011 ). Sensitization rates to Bet v 1 among birch -
allergic individuals reach >95% (Erler, 2011 ) (Jarolim, 1989 ) (Schenk, 2011 ). Birch polle n 
exposure is associated with an increase in asthma -related emergency department visits 
(Guilbert,  2018 ) (Ito, 2015 ). Up to 70% of people with pollen allergy also experience oral reactions 
to particular fresh fruits, vegetables, and nuts, a condition known as oral allergy syndrome (OAS), 
or pollen food allergy syndrome (PFAS). Pollen food allergy syndrome is not a separate food 
allergy but rather occurs because of cross -reactive epi[INVESTIGATOR_550016] 
(Ebner, 1995 ) (Vanek -Krebitz, 1995 ). Pollen food allergy syndrome symptoms typi[INVESTIGATOR_550017], mouth, a nd throat, but potentially involve lip and tongue swelling and 
angioedema (Bucher, 2004 ) (Eriksson, 1982 ), leading people to avoid these fresh fruits, 
vegetables, and nuts. Approximately 70% of people with birch allergy also have PFAS to foods 
with si milar epi[INVESTIGATOR_550018] v 1, such as apple, carrot, stone fruits, and hazelnut 
(Biedermann,  2019b ). 
Antihistamines and intra -nasal corticosteroids are first line therapy for allergic rhinitis, but only 
provide poor or partial symptom control and short -term relief to over half of allergic rhinitis 
sufferers (Halken, 2017 ) (Wallace, 2017a ) (Wallace, 2008 ) (Wallace, 2017b ) (Wei, 2016 ). Second 
line therapy for allergic rhinitis is allergen -specific immunotherapy (SIT), taken as either 
subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) tablets or drops 
(Bousquet, 1998 ) (Calderon, 2007 ) (Durham, 1999 ) (Ewbank, 2003 ) (Nelson, 2004 ) 
(Walker, 2001 ). Birch pollen SIT is used to treat birch -sensitive allergic rhinitis, including 
allergies caused by [CONTACT_550045] (eg, alder  and hazel) 
(Biedermann, 2019a ) (Makela, 2018 ) (Mauro, 2007 ). Birch  pollen SIT has been shown to reduce 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 17 
CONFIDENTIAL  asthma  medication use and to reduce the risk of new -onset  asthma (Wahn, 2019 ). Immunotherapy 
using natural or recombinant Bet v [ADDRESS_721359] in 
reducing daily allergic rhinitis symptom scores compared to placebo groups, highlighting the 
immunodominance of Bet v 1 in birch  pollen allergy (Pauli, 2008 ). Moreover, in vitro inhibition 
studies with birch pollen have shown a high degree of inhibit ion of human IgE binding to alder, 
hazel, and oak allergen extracts (Niederberger, 1998 ). Studies also demonstrate that birc h pollen 
SIT may offer symptom amelioration of PFAS (Asero, 1998 ) (Asero, 2003 ) (Asero, 2004 ) 
(Bergmann, 2008 ) (Bolhaar, 200 4) (Herrmann, 1995 ) (Kelso, 1995 ). 
However, SIT has man y limitations. For the treatment of allergic rhinitis, SCIT or SLIT must be 
administered for at least 2 to 6 months prior to the onset of efficacy, and the efficacy of SIT requires 
high adherence to prevent rhinitis symptoms upon allergen exposure (Biedermann, 2019a ) 
(Demoly, 2016 ) (Didier, 2011 ) (Durham, 201 0) (Durham, 2012 ) (Durham, 2016 ) (Durham, 1999 ) 
(Lemberg, 2017 ) (Nolte, 2016 ). Subcutaneous immunotherapy is administered weekly during 
initiation of therapy and then monthly, under direct supervision in the clinic. Sublingual 
immunotherapy is administered daily at home. Both SCIT and SLIT have a high incidence of 
adverse events (AEs), including anaphylaxis. A naphylaxis does not typi[INVESTIGATOR_550019], 
environmental pollen exposure. When allergens are administered through immunotherapy, there 
is higher allergen exposure, and therefore, there is risk of more significant allergic reactions 
including anaphyl axis. Anaphylaxis occurs more frequently with SCIT (up to 0.4%, affecting 7% 
of treated patients) compared to SLIT (Epstein, 2017 ). Since SLIT is administered a t home, even 
though the risk of anaphylaxis with SLIT is lower compared to SCIT, any risk of severe allergic 
reactions causes a significant safety concern. Reactions to SCIT occur in 40% to 50% of patients, 
ranging from mild (eg,  swelling, injection site r eaction, de novo allergic response, and urticaria) 
to life -threatening (eg, asthma exacerbation and anaphylaxis) (Frew, 2006a ) (Frew, 2010 ) 
(Frew,  2006b ). Reactions to SLI T occur in the majority of patients, commonly involving irritation 
or swelling in the mouth or throat, predominantly over the first few weeks of therapy 
(Biedermann,  2019a ). Subcutaneous immunotherapy and SLIT are generally contraindicated in 
patients with moderate to severe asthma (Cox, 2011 ). 
Adherence to SIT is poo r, likely due to the slow time to onset of action, the significant risk of 
allergic reactions, and the requirement for strict adherence for efficacy, including frequent clinic 
visits and monitoring needs in the case of SCIT (Musa, 2017 ). Due to these limitations, there 
remains an unmet need for a more robust, safer, rapid, and more convenient ther apeutic approach 
for the prevention and treatment of moderate to severe allergic rhinitis and comorbid asthma.  
1.2. Monoclonal Antibodies for the Treatment of Allergic Diseases  
It has been hypothesized that high -affinity monoclonal “blocking antibodies” could be developed 
and administered as a form of passive immunotherapy for the treatment of allergy. This concept 
grew out of the observation that allergen -specific polyclonal IgG4 titers increase during SIT and 
may inhibit effector cell activation by [CONTACT_47506] a llergen -binding to mast cell and basophil 
membrane -bound, high -affinity IgE receptors, effectively preventing early -phase allergic 
symptoms. During SIT, clinical symptom improvement correlates with the ability of blocking 
IgG4s to compete with IgE for alle rgen-binding (James, 2011 ) (Uermosi, 2010 ). To test the 
hypothesis that IgG4 blockade to an allergen can reduce allergic symptoms upon exposure to the 
allergen , a cocktail of 2 IgG4 monoclonal antibodies (mAbs; REGN1908 -1909) that bind to 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 18 
CONFIDENTIAL  Fel d 1, the major allergen in cat dander, was developed. In allergic rhinitis patients with cat 
allergy, when symptom reduction was evaluated in a nasal allergen challenge mod el following 
administration of REGN1908 -1909, total nasal symptom score (TNSS) area under the curve 
(AUC; hour 0 to 1) was reduced in REGN1908 -1909 -treated patients compared to placebo at days 
8, 29, and 85 (p = 0.0005, p = 0.0004, and p = 0.0187, respecti vely; by [CONTACT_144406] 
[ANCOVA]) (Orengo, 2018 ). 
1.3. REGN5713, REGN5714, and REGN5715: Fully Human Monoclonal Antibodies 
Against Bet v 1  
Similar to REGN1908 -1909 (Orengo, 2018 ), [ADDRESS_721360] Bet v 1 (REG N5713, 
REGN5714, and REGN5715) have been developed for the treatment of birch allergy. Preclinical 
studies demonstrate that the 3 mAbs bind independently and non -competitively to the Bet v 1 
allergen. Data also indicate that all 3 mAbs are required to opti mally inhibit binding of Bet v 1 to 
human polyclonal IgE, and thus reduce in vitro effector cell degranulation and subsequent Type 1 
hypersensitivity reaction. A single ascending dose -escalation clinical trial of the 3 mAb cocktail 
(REGN5713 -5714 -5715; in 1:1:1 ratio) has been completed and demonstrated that a single 150 mg 
subcutaneous (SC), 450 mg SC, 900 mg SC, or 900 mg intravenous (IV) dose had a favorable 
safety profile and was well -tolerated for [ADDRESS_721361] -dose, which was the follow -up period for 
the study.  
In a phase 1b proof -of-concept (POC) study conducted in subjects with birch allergy (N=64), a 
single 900 mg SC dose of REGN5713 -5714 -5715 (300 mg per mAb) prophylactically blocked 
early allergic response to nasal challenge with birch allergen 8, 29, and [ADDRESS_721362] -dose, result ing 
in a 32%, 27%, and 19% improvement in TNSS AUC (hour 0 to 1), respectively, relative to 
placebo. Subjects showed improvement [ADDRESS_721363] (SPT) was also observed up to [ADDRESS_721364] -dose, as 
measured by a significant reduction in the AUC of the  SPT mean wheal diameters relative to 
placebo (placebo -adjusted percent changes relative to the baseline SPT of -72.39%,  
-65.61%, -77.90%, and -73.56% on study days 8, 29, 57, and 113, respectively). Overall, 
REGN5713 -5714 -5715 was well tolerated, with no  anaphylaxis or evidence of hypersensitivity 
observed. Basophil activation tests (BAT) were also performed on a subset of subjects to 
characterize immune modulation during treatment. Significant suppression of basophil 
responsiveness to birch, alder, and h azel pollen extract was observed with treatment (n=13) versus 
placebo (n=13) as measured by [CONTACT_550046] 50 (birch and alder on days 8, 
57, 113, all p <0.001; hazel on day 8, p <0.001, on day 57, p = 0.01). Thus, clinical efficacy of 
anti-Bet v [ADDRESS_721365] cell -mediated allergic responses  and may also be extended to those allergic to 
birch homologous trees such as alder and hazel. Pharmacokinetic (PK) and pharmacodynamic 
(PD) data also support the use of a single 900 mg SC dose of REGN5713 -5714 -5715 (300 mg per 
mAb) to prevent allergy symptoms and reduce the need for rescue medication for the duration of 
birch pollen season.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721366] administration of 
allergen -specific mAbs may offer a rapid and effective approach to reducing allergic symptoms. 
Utilizing human mAbs such as REGN5713 -5714 -5715 to treat birch allergy may overcome several 
limitations currently hampering SIT. As compared to SIT, blocking mAbs may:  
• Be safer: As the allergic subject is not exposed to native allergen, there is less risk of 
hypersensitivity events related to treatment.  
• Have a faster onset of action: For example, a single SC dose of 900 mg 
REGN5713 -5714 -5715 demonstrated clinical efficacy after 8 days (the earliest time 
point evaluated).  
• Offer more predictable efficacy: SIT efficacy is variable depending on how well the 
patient tolerates up  dosing.  
• Offer more conve nience: A single SC dose may treat allergic symptoms for the entire 
birch pollen season. The patient would not be constrained to a rigorous weekly or 
monthly schedule as is the case for SIT.  
• Potentially broaden benefit to include allergic reactions induced  by [CONTACT_550047] -tree 
homologous pollens and/or birch related foods.  
• Offer an effective treatment option to patients with more persistent or uncontrolled 
asthma who may have previously been contraindicated to receive SIT.  
This phase 3 randomized, double -blind, placebo -controlled study will assess the efficacy of 
REGN5713 -5714 -5715 to reduce allergic rhinitis and conjunctivitis symptoms and the use of 
rescue medications in the field during birch pollen season. Additional bac kground information on 
the study drug and development program can be found in the Investigator’s Brochure.  
2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective is to assess the reduction of allergic symptoms as measured by [CONTACT_550048] (CSMS) during birch pollen season after a single dose of 
REGN5713 -5714 -5715 versus placebo.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 20 
CONFIDENTIAL  2.2. Secondary Objectives  
The secondary objectives are:  
• To assess the reduction of allergic symptoms and use of allergy -relieving medications 
after a single do se of REGN5713 -5714 -5715 versus placebo, as measured by [CONTACT_550049] (TSS), total nasal symptom score (TNSS), total ocular symptom score 
(TOSS), and daily medication score (DMS)  
• To evaluate the safety and tolerability of REGN5713 -5714 -5715, incl uding the 
incidence of hypersensitivity reactions and local injection site reactions  
• To evaluate the reduction in early allergic response to birch allergen after a single dose 
of REGN5713 -5714 -5715 versus placebo, as measured by [CONTACT_550039]  
• To determine systemic exposure of total antibody (ie, free and antigen -bound) in the 
form of concentration of REGN5713, REGN5714, and REGN5715 in serum  
• To assess the immunogenicity to REGN5713, REGN5714, and REGN5715 in subjects 
after a single dose of REGN571 3-5714 -5715  
• To evaluate “well days”  
Note: “Well days” are defined as days when the TSS is ≤2 without the use of anti -
allergy rescue medications.  
2.3. Exploratory Objectives  
The exploratory objectives are:  
• To assess asthma control as measured by [CONTACT_550037] (ACQ -5) 
• To assess quality of life as measured by [CONTACT_550038] (RQLQ [S])  
• To evaluate the reduction in early allergic response to birch homologous allergens 
(alder  and oak) as measured by [CONTACT_550050] m ean wheal diameter  
• To assess the relationship between allergy sensitization status to Bet v 1 or birch pollen 
at screening (as measured by [CONTACT_550040] -IgE [sIgE]) and clinical response 
to REGN5713 -5714 -5715 treatment  
• To assess serum sIgE level s against Bet v 1 and birch pollen during birch pollen season 
to evaluate the relationship between the response to REGN5713 -5714 -5715 and change 
in sIgE levels in -season  
• To assess the inhibitory effect of REGN5713 -5714 -5715 on the binding of endogenous 
serum IgE to birch allergen in an in vitro assay; to assess whether the degree of 
inhibition correlates with clinical improvement  
• To assess sIgE levels against other allergens (eg, Bet v 2, alder and oak) at screening 
and to evaluate the relationship betwee n response to REGN5713 -5714 -5715 and poly -
allergic status  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 21 
CONFIDENTIAL  • To assess additional subclasses of serum antibodies (eg, total IgG and IgG4 against 
birch pollen and Bet v 1) to evaluate the relationship between endogenous anti -Bet v 1 
antibodies and response to REGN5713 -5714 -5715  
• To assess the reduction in PFAS and related symptoms as measured by [CONTACT_550051] (PFASQ)  
• To assess patient rating of severity of seasonal allergy symptoms as measured by 
[CONTACT_550052]  (PGI -S) 
3. HYPOTHESIS AND RATIO NALE  
3.1. Hypothesis  
A single SC dose of REGN5713 -5714 -5715 is more effective than placebo in the reduction of 
CSMS during birch pollen season.  
Refer to Section  11.1 for the statistical hypothesis.  
3.2. Rationale  
3.2.1.  Rationale for Study Design  
Study design and duration  
This is a phase 3 multi -center, randomized, double -blind, placebo -controlled, parallel group study 
to assess the efficacy of anti -Bet v 1 mAbs ( REGN5713 -5714 -5715) to reduce allergic rhinitis and 
conjunctivitis during birch pollen season. The study will last approximately 28 weeks, including 
screening (refer to Table  1 for a schedule of events). The actual duration of the study will vary 
depending on the start, peak, and end dates of the local birch pollen season for each study site, 
which will be variable across d ifferent geographies (refer to Section  9.2.2 ):  
• Screening : Generally healthy male and female subjects [ADDRESS_721367] 2 years will undergo screening visits before the onset 
of the birch pollen season. Subjects will be asked to refrain from taking specific 
prohibited medications within the specified period preceding screening (refer to 
Section  8.9.1 ).  
• Randomization : Candidate subjects who meet all inclusion and no exclusion criteria 
will be randomized and receive the study drug. Randomization will be str atified based 
on geographical regions and sIgE levels at screening (refer to Section  8.5).  
• In-season visits : Approximately 1 month after randomization  (timing will vary based 
on the local pollen season), a telephone contact [CONTACT_550053]. There will be an in -clinic visit at the anticipated 
local peak of birch pollen season. An additional telephone c ontact will occur at the end 
of the local birch pollen season. An in -clinic visit will occur at the end of the study. 
Subjects will be asked to stop using specific rescue medications within 5 days of the 
end of study visit (refer to Section  8.9.1 ).  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721368] symptom scores (TNSS, TOSS) daily. Subjects will be provided with rescue 
medications to treat allergic symptoms d uring the study (refer to Section  8.2) to treat their allergic 
rhinitis with or without conjunctivitis. Subjects will be asked to record their daily u se of rescue 
medications using an e -diary throughout the birch pollen season to calculate the DMS. TNSS and 
TOSS are scored for a combined TSS. The TSS and DMS are combined for the CSMS.  
ACQ -[ADDRESS_721369] 
quality of life, RQLQ (S) will be assessed weekly in all subjects. In addition, PFASQ and PGI -S 
will be administered throughout the study to assess treatment effects on PFAS symptoms and 
overall patient impression of severity. R efer to Section  9.2.4  for more details on these efficacy 
measures.  
Primary objective  
The primary objective of the study is to assess the reduction of  allergic symptoms as measured by 
[CONTACT_550054] a single dose of REGN5713 -5714 -5715 versus placebo. 
The primary endpoint is CSMS, averaged over the duration of the birch pollen season, in subjects 
who receive a single dose of REGN57 13-5714 -5715 versus placebo. Based on recent reviews of 
SLIT products, for registration, the Food and Drug Administration (FDA) expects a treatment to 
reduce average CSMS by [CONTACT_2669] 15% compared to placebo. The European Medicines Agency 
(EMA) has a set a similar standard (approximately 20% compared to placebo) based on guidance 
from the World Allergy Organization (WAO) task force (Canonica, 2014 ). As CSMS is the 
recommended endpoint for in -field studies for allergic rhinitis treatments, this study will provide 
data on the treatment effect of REGN5713 -5714 -5715 on the CSM S.  
Secondary objectives  
A secondary objective of the study is to evaluate the average TSS, TNSS, TOSS, and DMS during 
birch pollen season comparing subjects who receive a single dose of REGN5713 -5714 -5715 
versus placebo.  
Incidence rates of treatment -emergent AEs (TEAEs) and serious TEAEs, as well as 
hypersensitivity reactions and local injection site reactions, will be collected to determine safety 
and tolerability of REGN5713 -5714 -5715.  
Total concentration of REGN5713, R EGN5714, and REGN5715 in serum will be assessed to 
determine systemic exposure of total antibody (ie, free and antigen -bound) throughout the study. 
In addition, immunogenicity to REGN5713, REGN5714, and REGN5715, as determined by [CONTACT_550055], titer and c linical impact of treatment -emergent ADA responses will be assessed.  
“Well days” will also be assessed. Well days are defined as days when rescue medication is not 
utilized and the TSS is ≤2/18. This exploratory objective will provide information about the  
number of days a patient is not affected by [CONTACT_550056].  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 23 
CONFIDENTIAL  Exploratory objectives  
Sensitization to birch and birch homologous group (alder  and oak) will be assessed by [CONTACT_550057] a single 900 mg SC dose of REGN5713 -5714 -5715 or placebo.  
Because these anti -Bet v 1 mAbs target Bet v 1 specifically, exploratory objectives will assess 
whether their efficacy is related to baseline levels of specific IgE to birch and Bet v 1. As it is 
known that allergen -specific IgE (sIgE) lev els increase during the natural pollen season, other 
exploratory objectives are to determine whether efficacy is related to changes in birch and Bet v 1 
sIgE. In addition, allergen sensitization to a panel of allergens, including but not limited to alder  
and oak, will be determined by [CONTACT_550058] (cutoff value 0.35 kUa). Also , of interest is 
whether the treatment response is associated with circulating levels of anti -birch or anti -Bet v [ADDRESS_721370] -in-
human (FIH) study, which was conducted in healthy, birch -allergic subjects. In that study, a single 
dose of 900 mg SC REGN5713 -5714 -5715 (300 mg per mAb) resulted in a significant reduction 
in allergic rhinitis symptoms following a nasal allergen challe nge for at least [ADDRESS_721371] -dose in healthy subjects who were allergic to birch pollen. This dose was 
well-tolerated, with TEAEs generally of  a mild to moderate severity, and occurred in similar rates 
in the placebo and REGN5713 -5714 -5715 treatment groups.  
REGN5713 -5714 -5715 exhibited linear PK. Throughout the duration of the study, the 
concentration of total REGN5713 -5714 -5715 in serum was ma intained above 10 mg/L, which had 
been identified from preclinical testing in the mouse percutaneous anaphylaxis (PCA) model as 
the concentration above which response to Bet v 1 was fully blocked.  
Based on the above summary of safety, PK, and PD data, a si ngle 900 mg SC dose of 
REGN  5713 -5714 -5715 (300 mg per mAb) is expected to prevent allergic symptoms and reduce 
the need for rescue medication for the duration of birch pollen season. Additional information on 
clinical and preclinical PK, PD, and safety ca n be found in the Investigator's Brochure.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 24 
CONFIDENTIAL  3.2.3.  Rationale for the Selected Anti -Bet v 1 Monoclonal Antibody Cocktail  
Preclinical studies were conducted to determine the optimal combination of anti -Bet v 1 mAbs 
REGN5713, REGN5714, and REGN5715. In addition to binding assays showing simultaneous, 
non-competitive binding to Bet v 1, a BAT using peripheral blood mononuclear cells (PBMCs) 
from birch -allergic donors showed near complete blocking efficacy using the 3 -mAb cocktail. 
Specifically, when REGN5713 -5714 -5715 were added as a cocktail, there was 97% median 
blocking of Bet v 1 -induced basophil activation with ≥90% blockade observed in 9 of 10 donors 
tested. The single antibodies (REGN5713, REGN5714, and REGN5715) achieved a median of 
50%, 55%, and 67% blocking,  respectively, reaching ≥90% blockade in only ≤[ADDRESS_721372] exogenous targets, including REGN1908 and 
REGN1909 (for Fed d 1); REGN10933 and REGN10987 (for SARS -CoV -2); atoltivimab, 
odesivimab, and maftivimab (f or Ebola); REGN3048 and REGN3051 (for MERS -CoV), and 
suptavumab (for respi[INVESTIGATOR_4345] [RSV]). These mAbs demonstrated specificity to their 
exogenous targets with no significant safety findings and low incidence of hypersensitivity, 
injection sit e reactions, or immunogenicity. Similarly, REGN5713 -5714 -5715 was generally well -
tolerated in the FIH study. In Part B of the FIH study, the overall frequency of treatment -related 
TEAEs was comparable between REGN5713 -5714 -5715 (21.9%) and placebo (25.0%),  all of 
which were of mild or moderate intensity and resolved without sequalae. There were no SAEs or 
AEs leading to study discontinuation/death.  
3.3. Risk -Benefit  
REGN5713 -5714 -5715 has been administered as a single dose to 56 healthy adult subjects 
(24 withou t known birch allergy and 32 with known birch allergy) in a FIH study with no 
significant clinical safety findings observed. No important identified risks have been established 
with REGN5713 -[ADDRESS_721373] other protein therapeutics that are administered SC, mild or moderate injection site 
reactions may occur and may be treated symptomatically. Allergy/hypersensitivity reactions may 
develop; the most concerni ng are those that may develop immediately or within a few hours of 
administration of REGN5713 -5714 -5715. Because REGN5713 -5714 -5715 is composed of 
antibodies whose sequence is fully human, the risk of these immediate reactions is considered to 
be extremely  low. Emergency equipment and medication for the treatment of these potential 
adverse effects (including but not limited to antihistamines, corticosteroids, acetaminophen, and/or 
epi[INVESTIGATOR_238]) are available for immediate use in this study. Considering the s afety data and the 
exogenous nature of the target antigen, the risk of other adverse reactions is considered to be 
extremely low. A risk -benefit statement with respect to the overall development program is 
provided in the Investigator’s Brochure.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 25 
CONFIDENTIAL  A Safety  Monitoring Team (SMT) will monitor blinded safety data on an ongoing basis to assess 
the risk -benefit profile of REGN5713 -5714 -5715 (refer to Section  6.3.1 ). Additionally, an 
Independent Data Monitoring Committee (IDMC) will be involved in the review of unblinded data 
in an ongoing manner (refer to Section  6.3.2 ). 
Recognizing that the Coronavirus Disease 2019 (COVID -19) pandemic will have an impact on the 
conduct of clinical trials, the Sponsor does not intend to screen any patients in this study until the 
impact of the COVID -[ADDRESS_721374] of trials at individual sites, and patients can safely participate in this study. Until then, the 
Sponsor plans to obtain approvals from Health Authorities/Ethics Committees to enable initiation 
of study sites for this study, as allowed by [CONTACT_10976].  
4. ENDPOINTS  
4.1. Primary Endpoint  
The primary endpoint is the daily CSMS, averaged over the duration of the birch pollen season, in 
subjects who receive a single dose of REGN5713 -5714 -5715 versus pla cebo.  
4.2. Secondary Endpoints  
The secondary endpoints are:  
• TSS, TNSS, and TOSS, averaged over the duration of the birch pollen season, in 
subjects who receive a single dose of REGN5713 -5714 -5715 versus placebo  
• DMS, averaged over the duration of the birch pollen season, in subjects who receive a 
single dose of REGN5713 -5714 -5715 versus placebo  
• Incidence of TEAEs and serious TEAEs throughout the study  
• Change and percent change from baseline to the end of study in birch SPT mean wheal 
diameter in subjects wh o receive a single dose of REGN5713 -5714 -5715 versus 
placebo  
• Total REGN5713, REGN5714, and REGN5715 concentration in serum over the study 
duration  
• Incidence of treatment emergent anti -drug antibodies (ADAs) to REGN5713, 
REGN5714, or REGN 5715 throughout th e study  
• The number of “well days” in each of the treatment groups, where the “well days” are 
defined as days when rescue medication is not utilized and the TSS is ≤2/18  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 26 
CONFIDENTIAL  4.3. Exploratory Endpoints  
The exploratory endpoints are:  
• ACQ -5, averaged over the duration of the birch pollen season, for REGN5713 -5714 -
5715 versus placebo  
• RQLQ (S), averaged over the duration of the birch pollen season, for REGN5713 -5714 -
5715 versus placebo  
• Change and percent change from baseline to the end of study in SPT mean wheal 
diamete r for birch homologous/cross -reactive allergens in REGN5713 -5714 -5715 
versus placebo  
• Baseline allergen -specific IgE levels and correlation with average CSMS, TSS, TNSS, 
TOSS, DMS during birch pollen season  
• Change and percent change from baseline to the pe ak of birch pollen season in allergen -
specific IgE  
• Change in inhibitory effect on serum IgE to birch allergen  
• Number of baseline sensitizations to other allergens (poly/mono -sensitization status, 
based on allergen -specific IgE levels) and correlation with  CSMS, TSS, TNSS, TOSS, 
and DMS, averaged over the duration of the birch pollen season  
• Baseline serum antibody levels and correlation with CSMS, TSS, TNSS, TOSS, and 
DMS, averaged over the duration of the birch pollen season  
• To assess the reduction in PFAS  and related symptoms, as measured by [CONTACT_550044], from 
baseline to end of study  
• To assess patient rating of severity of seasonal allergy symptoms, as measured by 
[CONTACT_380440]-S, from baseline to end of study  
5. STUDY VARIABLES  
5.1. Demographic and Baseline Characteristics  
Baseline characteristics will include standard demography (eg, age, race, weight, height, etc), 
medical history, medication history, asthma history, SPT mean wheal diameter, and serum sIgE 
levels for each subject.  
5.2. Efficacy Variables  
Efficacy variables include  TNSS, TOSS, TSS (which results from adding the TNSS and TOSS), 
DMS, CSMS (which results from adding the DMS and TSS), RQLQ (S), PFASQ, ACQ -5 (in 
subjects with a history of asthma), and PGI -S. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 27 
CONFIDENTIAL  5.3. Safety Variables  
Safety variables include AEs, vital signs, physical examinations, electrocardiogram (ECG), and 
laboratory safety tests.  
5.4. Pharmacokinetic Variables  
The PK variables are the concentrations of total REGN5713, REGN5714, and REGN5715 in 
serum at the sampling ti me points specified in Table  1. 
5.5. Immunogenicity Variables  
The immunogenicity variables are ADA status, titer, and time -point/visit. Samples for the 
asses sment of immunogenicity in this study will be collected at the clinic visits specified in 
Table  1. 
5.6. Pharmacodynamic and Other Biomarker Variables  
Explor atory biomarker variables include, but not be limited to: serum total IgE, serum sIgE for 
birch and Bet v 1, serum sIgE for concomitant allergens and homologous allergens, SPT results 
for birch, birch homologous, and other common allergens.  
These results may be reported outside of the clinical study report (CSR).  
5.7. Other Variables  
Outdoor pollen counts will be measured daily by [CONTACT_550059] a vendor during the expected 
pollen season using a pollen sampler.  
6. STUDY DESIGN  
6.1. Study Description and Duration  
This is a phase 3 multi -center, randomized, double -blind, placebo -controlled, parallel group study 
to assess the efficacy of REGN5713 -5714 -5715 to reduce allergic rhinitis and conjunctivitis 
symptoms and the use of rescue medications during birch pollen se ason.  
The total study duration is approximately 28 weeks including screening, dependent on the start 
and end times of the local birch pollen season ( Figure  1). The length of birch pollen season will 
vary based on geography. Approximately 300 birch -allergic subjects will be randomized 1:1 to 
REGN5713 -5714 -5715 or placebo (refer to Section  8.1 for more details) . 
Efficacy will be evaluated by [CONTACT_550060] n, after a single SC 
dose of REGN5713 -5714 -5715 or placebo. The incidence and severity of TEAEs, including 
hypersensitivity reactions and local injection site reactions, will also be assessed.  Total 
concentration in serum and immunogenicity of REGN5713, RE GN5714, and REGN5715 will be 
measured at the sampling times specified in Table  1.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 28 
CONFIDENTIAL  Figure  1: Study Flow Diagram  
 
6.1.1.  Study Stoppi[INVESTIGATOR_550020] a 
Regeneron SMT, a recommendation may be made to temporarily pause, alter, or terminate the 
study. Once SMT or IDMC recommendations have been receiv ed, further discussions and 
consultation with Regeneron Safety Oversight Committee (RSOC) may be conducted to determine 
if these or other actions should be taken. Refer to Section  6.3.[ADDRESS_721375] to follow -up (ie, the study subject can no longer be contact[CONTACT_24992]).  
6.2. Planned Interim Analysis  
No formal interim analysis will be conducted.  
A description of the statistical methods to be employed is in Section  11.5, and blinding 
implications are discussed in Section  8.6. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 29 
CONFIDENTIAL  6.3. Study Committees  
6.3.1.  Safety Monitoring Team  
A Regeneron SMT will meet periodically to review blinded safety data as needed. The team may 
be comprised of the Medical/Study Director, a Global Patient Safety representative, 
representatives from Biostatistics and Data Management, as well as representati ves from Clinical 
Operations and Regulatory Affairs. The data to be reviewed will include, but are not limited to:  
• Treatment -emergent adverse events that result in an early study withdrawal  
• Serious adverse events  
• Severe AEs  
• Selected laboratory tests, as d eemed appropriate by [CONTACT_35307]  
• Additional adverse events of special interest (AESIs), as defined in Section  10.1.[ADDRESS_721376] safety by [CONTACT_550061]; if requested, the IDMC may have 
access to the treatment allocation code or any other requested data for the purposes of a risk -benefit 
assessment. The IDMC will provid e the Sponsor with appropriate recommendations on the 
conduct of the clinical study to ensure the protection and safety of the subjects enrolled in these 
studies. All activities and responsibilities of the IDMC are described in the IDMC charter.  
7. SELECTION , WITHDRAWAL, AND RE PLACEMENT OF 
SUBJECTS  
7.1. Number of Subjects Planned  
Approximately 300 adult subjects will be enrolled at multiple sites in Canada, [LOCATION_002], and 
Europe.  
7.2. Study Population  
Generally healthy adult male and female subjects with birch alle rgy will be enrolled.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721377] meet the following criteria to be eligible for inclusion in the study:  
1. Generally healthy men and women [ADDRESS_721378] (ie, mean wheal diameter at least 5 mm greater than 
a negative control) in the screening period  
4. Positive sIgE tests for birch pollen and Bet v 1 (ie, ≥0.7 kUa/L) in the screening period  
5. Willing and able to comply with clinic visits and study -related procedures   
6. Provide informed consent signed by [CONTACT_550062]  
7. Able to understand and complete study -related questionnaires  
7.2.2.  Exclusion Criteria  
A subject who meets any of the following criteria will be excluded from the study:  
1. Participation in a prior REGN5713 -[ADDRESS_721379] with other allergens causing symptoms that are expected to coincide with 
birch pollen season, as assessed by [CONTACT_093]  
3. Subjects who anticipate major changes in allergen exposure in their home or w ork 
environments that are expected to coincide with study assessments, per investigator 
discretion  
4. Persistent chronic or recurring acute infection requiring treatment with antibiotics, 
antivirals, or antifungals, or any untreated respi[INVESTIGATOR_550021] 4 weeks prior to 
screening. Participants may be re -evaluated for eligibility after symptoms resolve  
5. Documentation of active SARS -CoV -2 infection  
Note: A subject with a documented, positive PCR or serology test for SARS -CoV-[ADDRESS_721380] has:  
• Recovered from COVID -19 (all COVID -19-related symptoms and major clinical 
findings which can potentially affect the safety of the patient should be resolved to 
baseline), and  
• Had 2 negative results from a health authority -authorized  nucleic acid amplification 
(PCR) test for COVID -[ADDRESS_721381] 48 hours apart  
6. Abnormal lung function as judged by [CONTACT_161461] 1 <70% of predicted at 
screening or randomization  
7. A clinical history of moderate to severe asthma with 2 or more asthma exacerbations 
requiring hospi[INVESTIGATOR_550022]-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721382] 2  years prior to screening  
9. History of nasal polyps  
10. Active lung disease other than asthma  
11. History of birch or related tree allergy immunotherapy (SCIT, SLIT, or oral 
immunotherapy) within [ADDRESS_721383] by [CONTACT_28224]   
15. Any physical examination findings and/or history o f any illness that, in the opi[INVESTIGATOR_50395], might confound the results of the study or pose an additional risk to the 
subject by [CONTACT_28224]   
16. Subjects with any laboratory findings showing evidence of organ dysfunction or any 
clinically significant deviation from the normal range, as decided by [CONTACT_550063], including but not limited to:  
a. Clinically significant/active underlying hepatobiliary disease  
b. Abnormal laboratory values at screening, such as:  
• Neutrophils <1.5 × 103/μL 
• Platelets <100,000 cells/mm3 
17. History of drug or alcohol abuse within a year prior to screening  
18. Any malignancy within the past [ADDRESS_721384] been resected, 
with no evidence of local recurrence or metastatic disease for 3 years  
19. Clinically significant abnormal ECG in the screening period as assessed by [CONTACT_093]  
20. History of acute hypersensitivity and/or anap hylaxis to excipi[INVESTIGATOR_550023] a substantial risk to the subject in the opi[INVESTIGATOR_1070]  
21. Treatment with an investigational drug or therapy within [ADDRESS_721385] 5 half -lives 
(if known), whic hever is longer   
22. Unwilling or unable to comply with the permitted and prohibited medication specifications 
for this study  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 32 
CONFIDENTIAL  23. Member of the clinical site study team and/or his/her immediate family, unless prior 
approval granted by [CONTACT_1034]   
24. Pregnant or breastfeeding women  
25. Women of childbearing potential (WOCBP)* who are unwilling to practice highly 
effective contraception prior to study drug administration, during the study, and for at least 
6 months after the dose of study medication. Highl y effective contraceptive measures 
include:  
a. stable use of combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal) or progestogen -only hormonal contraception (oral, 
injectable, implantable) associated with in hibition of ovulation initiated 2 or more 
menstrual cycles prior to screening,  
b. intrauterine device (IUD); intrauterine hormone -releasing system (IUS),  
c. bilateral tubal ligation,  
d. vasectomized partner (provided that the male vasectomized partner is the sole s exual 
partner of the WOCBP study participant and that the vasectomized partner has obtained 
medical assessment of surgical success for the procedure),  
e. and/or sexual abstinence†,‡. 
* WOCBP are defined as women who are fertile following menarche until becomi ng 
postmenopausal, unless permanently sterile. Permanent sterilization methods include 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], and bilateral oophorectomy.  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy. However, in the 
absence of 12 months of amenorrhea, a single FSH measurement is insufficient to 
determine the occurrence of a postmenopausal state. The above definitions are 
according to the Clinical Trial Facilitation Group (CTFG) guidance. Pregnancy 
testing and contraception are not required for women with documen ted hysterectomy 
or tubal ligation.  
† Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study drugs. The reliability of sexual abstinen ce needs to be evaluated in 
relation to the duration of the clinical trial and the preferred and usual lifestyle of the 
subject.  
‡ Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and  lactational amenorrhea method (LAM) are 
not acceptable methods of contraception. Female condom and male condom should 
not be used together.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 33 
CONFIDENTIAL  26. Sexually active men who are unwilling to use the following forms of medically acceptable 
birth control during the s tudy drug follow -up period and for 6 months after the study drug 
administration: vasectomy with medical assessment of surgical success or consistent use 
of a condom. Sperm donation is prohibited during the study and for up to [ADDRESS_721386] has the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or Sponsor have the right to withdraw a subject from the study if it is no 
longer in the interest of the subject to continue in the study, or if the subject’s continuation in the 
study places the scientific outcome of the study at risk  (eg, if a subject does not or cannot follow 
study procedures). An excessive rate of withdrawals would render the study uninterpretable; 
therefore, unnecessary withdrawal of subjects should be avoided.  
Subjects who are withdrawn prematurely from the study  will be asked to complete the early 
termination visit, as described in Section  9.1.2 . 
7.4. Replacement of Subjects  
Subjects who are randomized, receive s tudy drug, and/or are prematurely discontinued from study 
will not be replaced.  
8. STUDY TREATMENTS  
8.1. Investigational and Reference Treatments  
REGN5713, REGN5714, and REGN5715 are provided individually in open -label vials in carton. 
Each 20 mL vial contains 265  mg of lyophilized protein.  Matching placebo is provided as a 
lyophilized powder in 20 mL open -label vials in carton.  
Instructions are provided in the pharmacy manual to create the following treatments:  
• Single SC dose of REGN5713 -5714 -5715 900 mg (300 mg p er mAb)  
• Single SC dose of matching placebo that replaces REGN5713 -5714 -5715  
Randomization will be stratified as described in Section  8.5. 
8.2. Rescue Treatm ents 
Subjects will be provided with the following medications to treat allergic symptoms during the 
study:  
• Desloratadine 5 mg (second generation antihistamine)  
• Olopatadine 1 mg/mL (antihistamine eye drop)  
• Mometasone furoate 50 ug/dose (intranasal steroid)  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721387] their daily medication use using an e -diary, including information regarding which 
medications was used and the amount of the pre -specified medications  that was used. Utilization 
of rescue medications should be initiated when subjects reach a symptoms threshold of 
approximately TSS ≥4/18. Subjects will be provided with training to understand the severity of 
symptoms associated with a TSS ≥4/18.  
Subjects  should be instructed not to utilize rescue medications in the anticipation of the birch 
pollen season. Subjects should also be instructed not to utilize antihistamines (ie, desloratadine or 
olopatadine) for 5 days before the end of study visit.  
For skin p rick tests  
Local allergen exposure through SPT typi[INVESTIGATOR_550024] a short time. Uncommonly, systemic immediate or late allergic reactions can occur. Such 
reactions should be treated appropriately, at the discretion of the investigator. With the exception 
of severe or clinically concerning reactions (as judged by [CONTACT_093]), rescue treatments 
should be given after study endpoint data collection is obtained (eg, after the skin wheals are 
measured after application of allergen).  
8.3. Dose Modification and Study Treatment Discontinuation Rules  
This is a single dose study. Dose modification for an individual subject is not allowed. Study 
treatment discontinuation is not applicable to this study.  
8.4. Management  of Acute Reactions  
8.4.1.  Acute Injection Reactions  
[IP_ADDRESS].  Systemic Injection Reactions  
Emergency equipment and medication for the treatment of systemic reactions must be available 
for immediate use if required for treatment. All injection reactions must be reported a s AEs (as 
defined in Section  10.2.1 ) and graded using the grading scales as instructed in Section  10.2.4 . 
Acute systemic reactions following injection of study drug (SC) should be treated using clinical 
judgment to determine the appropriate response according to typi[INVESTIGATOR_24896].  
[IP_ADDRESS].  Local I njection Site Reactions  
Local injection site reactions must be reported as AEs and graded according to Section  10.2.4 . 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 35 
CONFIDENTIAL  8.5. Method of Treatment Assignment   
Subjects will be randomized according to a central randomization scheme provided by [CONTACT_458215] (IRT) to the designated study pharmacist (or qualified designee) as per 
Table  1.  
Subjects will be randomized 1:1 as below (refer to Section  8.1 for more details):  
• REGN5713 -5714 -5715  
• Matching placebo  
Randomization will be stratified based on the following:  
• Serum specific birch pollen IgE levels at screening (<17.5 kUa/L versus ≥17. 5 kUa/L)  
• In North America only:  Serum specific oak pollen IgE levels at screening 
(<0.7  kUa/L versus ≥0.7 kUa/L)  
• Geographical region (North America versus Europe)  
8.6. Blinding  
Study subjects, the principal investigators, and study site personnel (excluding the unblinded 
pharmacy staff) will remain blinded to all randomization assignments throughout the study. The 
Regeneron Medical/Study Director, Study Monitor, and any other Regeneron and contract research 
organization (CRO) personnel who are in regular cont act with the study site will remain blinded 
to all subject randomization assignments.  
Selected individuals not involved in the conduct of the study may have access to unblinded data 
as needed for safety review or other data review.   
8.7. Emergency Unblinding  
Unblinding of treatment assignment for a subject may be necessary due to a medical emergency 
or any other significant medical event (eg,  pregnancy) and when a treatment decision is contingent 
on knowing the subject's treatment assignment.  
• If unblinding is r equired:  
− Only the investigator will make the decision to unblind the treatment assignment  
− Only the affected subjects will be unblinded  
− The designated study pharmacist(s)/designee at the study site will provide the 
treatment assignment to the investigator. If there is no study pharmacist, the 
investigator for the site will unblind/unmask the subject. Unblinding is performed 
using the interactive voice/web response system (IVRS/IWRS) which will notify 
Regeneron  
− The investigator will notify Regeneron and/or de signee as soon as possible after 
unblinding the subject  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721388] (when applicable), at any time during the conduct of the study, except in the case of a 
true eme rgency and when a treatment decision is contingent on knowing the subject's treatment 
assignment. In the event that there is no study pharmacist, the individual at the site fulfilling that 
role will be the only unblinded member of the site personnel.  
8.8. Treat ment Logistics and Accountability  
8.8.1.  Packaging, Labeling, and Storage  
A medication numbering system will be used to label blinded investigational study drug. Lists 
linking medication numbers with product lot numbers will be maintained by [CONTACT_25006] (or 
compa nies) responsible for study drug packaging. In order to maintain the blind, these lists will 
not be accessible to individuals involved in study conduct.  
The unblinded pharmacist will prepare the unblinded investigational product and dispense it in a 
blinde d manner to the blinded study staff for administration to the subject.  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; storage instructions will be 
provided in the pharmacy manual.  
8.8.2.  Supply and Disposition of Treatments  
Study drug wil l be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study. At specified time points during the study (eg, interim site 
monitoring visits), at the site close -out visit, and following drug reconciliation and documentation 
by [CONTACT_25007], all opened and unopened study drug will be destroyed at site with approval by 
[CONTACT_550064].  
Rescue medications may be procured and distributed by [CONTACT_3452].  
8.8.3.  Treatment Acco untability  
All drug accountability records must be kept current.  
The investigator must be able to account for all opened and unopened study drug. These records 
should contain the dates, quantity, and study medication:  
• Dispensed to each subject  
• Returned fro m each subject (if applicable)  
• Disposed of at the site or returned to the Sponsor or designee  
All accountability records must be made available for inspection by [CONTACT_103239]; photocopi[INVESTIGATOR_550025] t he conclusion of the study.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721389] be kept current and made available for inspection by [CONTACT_550065].  
8.9. Concomitant Medications  
Any treatment administered from the time of informed consent to the final study visit will be 
considered concomitant medication. This includes medications that were started before the study 
and ar e ongoing during the study.  
8.9.1.  Prohibited Medications  
Preceding screening  
Use of the below concomitant medications is prohibited within the following time period preceding 
the screening and randomization visits:  
• Topi[INVESTIGATOR_550026] H1 antih istamines (eg, diphenhydramine and 
chlorpheniramine) (3 days)  
• Second generation and long -acting H1 antihistamines (eg, cetirizine) (5 days)  
• Cromoglycates (14 days)  
• Leukotriene modifiers (30 days)  
• Intranasal corticosteroids (14 days)  
• Systemic steroid treatm ent (30 days)  
• Topi[INVESTIGATOR_8826], with the exception of hydrocortisone (≤1%) (48 hours)  
• Anticholinergics (eg, Ipratropi[INVESTIGATOR_1890] [Atrovent 40 μg]) (12 hours)  
• Intramuscular corticosteroids (3 months prior to screening and during the study)  
• Systemic or topi[INVESTIGATOR_110405] (14 days prior to screening and during the 
study)  
• Topi[INVESTIGATOR_550027] (72 hours)  
• Tricyclic antidepressants/typi[INVESTIGATOR_16709] (14 days)  
• Birch -specific allergen immunotherapy (5 years)  
• Immune -directed biologic therapi[INVESTIGATOR_550028] 2 allergic disease 
or suppress the immune system (6 months)  
• Long -acting anti -muscarinic agents (7 days)  
• Ultra -long-acting β -agonists (eg, indacaterol, vilanterol, olodaterol) (14 days)  
• Methylxanthines (eg, oral theophylline) (24 h ours)  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 38 
CONFIDENTIAL  Preceding the end of study visit  
Use of the below medications is prohibited within the following time period preceding the end of 
study visit. Refer to Section  8.2 for more information on rescue medications:  
• Desloratadine (5 days)  
• Olopatadine (5 days)  
• Topi[INVESTIGATOR_8826], with the exception of hydrocortisone (≤1%) (48 hours)  
Any time throughout the study  
• Anticholinergics  
• Leukotriene modifiers  
• Cromoglycates  
• Topi[INVESTIGATOR_550027]  
• Systemic steroid treatment  
• Tricyclic antidepressants/typi[INVESTIGATOR_16709]  
• Any allergen immunotherapy  
• Immune -directed biologics therapi[INVESTIGATOR_550028] 2 allergic disease 
or suppress the immune  system  
• Methylxanthines (eg, oral theophylline)  
• Anti-allergic medications (antihistamines, anti -allergic eye drops, anti -allergic nasal 
sprays) outside of study -related anti -allergic medications as they will be supplied as 
part of the study (refer to Secti on 8.2) 
8.9.2.  Permitted Medications  
Use of standard -of-care medications not prohibited per Section  8.9.1  will be allowed. Treatment 
for acute reactions is allowed during the study (see Section  8.2). 
9. STUDY SCHEDULE OF EVE NTS AND PROCEDURES  
9.1. Schedule of Events  
In light of the public health emergency related to COVID -19, the continuity of clinical study 
conduct and oversight may require implementation of temporary or alternative mechanisms. 
Examples of suc h mechanisms may include, but are not limited to, any of the following: phone 
contact, virtual visits, telemedicine visits, online meetings, non -invasive remote monitoring 
devices, use of local clinic or laboratory locations, and home visits by [CONTACT_550066]. Additionally, 
no waivers to deviate from protocol enrollment criteria due to COVID -[ADDRESS_721390] only for the duration of the 
public health emergency.  
Study assessments and procedures are presented by [CONTACT_25010]  1.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 39 
CONFIDENTIAL  Table  1: Schedule of Events  
 SCREENING 
PERIOD  TREATMENT PERIOD  FOLLOW -UP PERIOD   
Study Procedure  Screening  
Visit 11 Randomization 
Visit 22-4 Visit 3  
Tel. Visit 4  
Tel. Visit 53 Visit 6  
Tel. EOS/ET  
Visit 73 Unscheduled 
Visit 
Day -84 to -7 13 2 283 573 85 1133  
Window (Days)  +7 ±3  ±7 ±14 ±14 ±14  
Inclusion/exclusion2 X X       
Informed consent  X        
Medical history  X4         
Demographics  X        
SPT for birch and birch homologous allergens and 
select regional or relevant allergens1 X      X  
Standard regional SPT for birch and other common 
allergens1 X        
FSH (in postmenopausal women)  X        
Treatment  
Randomization2  X       
Study drug administration2  X       
Efficacy  
E-diary and rescue medications dispensation/return5  X     X  
TNSS6  Daily via e -diary   
TOSS6  Daily via e -diary   
DMS6  Daily via e-diary   
ACQ -5 (in subjects with asthma)7  Weekly via e -diary  X 
RQLQ (S)8  Weekly via e -diary  X 
PFASQ9  X     X  
PGI-S10  X   X  X  
Safety  
Vital signs11 X X11   X   X 
Physical examination12 X X     X X 
ECG  X        
AEs X X X X X X X X 
Height  X        
Weight  X        
Concomitant medications  X X X X X X X X 
Spi[INVESTIGATOR_038]  X4 X      X 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 40 
CONFIDENTIAL   SCREENING 
PERIOD  TREATMENT PERIOD  FOLLOW -UP PERIOD   
Study Procedure  Screening  
Visit 11 Randomization 
Visit 22-4 Visit 3  
Tel. Visit 4  
Tel. Visit 53 Visit 6  
Tel. EOS/ET  
Visit 73 Unscheduled 
Visit 
Day -84 to -7 13 2 283 573 85 1133  
Window (Days)  +7 ±3  ±7 ±14 ±14 ±[ADDRESS_721391], urine (in WOCBP)[ADDRESS_721392], serum (in WOCBP)13 X       X 
Urinalysis  X       X 
Serum total IgE   X   X  X  
Serum sIgE for birch pollen and Bet v 1 and other 
regional or relevant allergens  X X   X  X X 
Serum sIgE for concomitant and homologous 
allergens   X   X  X  
Interference assay, serum   X       
Pharmacokinetics and Immunogenicity  
PK14  X14   X  X X 
ADA14  X14     X X 
Biomarkers and Pharmacogenomics  
FBR samples, serum and plasma (optional)15  X   X  X  
Genomic DNA sample (optional)16  X16       
ACQ -5=asthma control questionnaire -5; ADA=anti -drug antibody; AE=adverse event; DMS=daily medication score; ECG=electrocardiogram; EOS=end of 
study; ET=early termination; FBR=future biomedical research; FSH=follicle stimulating hormone; PFASQ=pollen food allergy symp tom questionnaire; PGI -
S=pa tient global impression of severity; PK=pharmacokinetics; RQLQ (S)=standardized rhinoconjunctivitis quality of life questionn aire; sIgE=allergen -specific 
immunoglobulin E; SPT=skin prick test; Tel=telephone; TNSS=total nasal symptom score; TOSS=total ocula r symptom score; WOCBP=women of childbearing 
potential.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721393] for birch should be performed 
prior to other screening assessments. If screening SPT for birch is negative (ie, mean wheal 
diameter < 5 mm greater than a negative control), then other screening visit procedures do 
not need to be performed as the subject will have failed screening (refer to Section  7.2.1  
Inclusion Criteria, #3 ).  
2. Randomization may occur within [ADDRESS_721394] the 
inclusion/exclusion criteria prior to study drug adm inistration.  
3. The timing of in -clinic visits may vary for each study site, depending on the start, peak, 
and end dates of the local birch pollen season  (as determined by [CONTACT_550067]; refer 
to Section  9.2.2 ). The randomization visit will be scheduled approximately 2 weeks before 
the start of birch pollen season, and the end of study (EOS) visit approximately 16 weeks 
after the randomization visit  (depending on the duration of the local birch pollen season). 
In addition, visit 5 will be scheduled to occur within 2 weeks of the anticipated local peak 
of the birch pollen season.  
4. If randomization occurs >[ADDRESS_721395] be repeated prior to randomization.  
5. E-diary and rescue medications will be dispensed at the randomization visit. E -diary and 
any unused rescue medications will be returned at the EOS visit. Refer to  Section  8.2 for 
more information on rescue treatments.  
6. TNSS, TOSS, and DMS will be recorded daily via e -diary, starting at the randomization 
visit unt il EOS. Refer to Section  [IP_ADDRESS] , Section  [IP_ADDRESS] , and Section  [IP_ADDRESS]  for procedural 
details.  
7. In asthmatic subjects, ACQ -5 scores will be recorded weekly via e -diary, starting from the 
randomi zation visit until EOS. Refer to Section  [IP_ADDRESS]  for procedural details.  
8. In all subjects, RQLQ (S) scores will be recorded weekly via e -diary starting  from the 
randomization visit until EOS. Refer to Section  [IP_ADDRESS]  for procedural details. In asthmatic 
subjects, the weekly RQLQ (S) and ACQ -5 assessm ents may be performed on the same 
day.  
9. Refer to for Section  [IP_ADDRESS]  procedural details.  
10. Refer to for Section  [IP_ADDRESS]  procedural details.  
11. Vital signs include systolic and diastolic blood pressure, respi[INVESTIGATOR_12463]. 
Vital signs will be collected in a seated position. At the randomizati on visit, vital signs are 
taken prior to PK blood draw, prior to study drug administration, and at 2 hours (±10  min) 
after completion of the injection.  
12. A full physical exam must be performed at screening, at baseline, and at EOS. A limited 
physical exam w ill be done at remaining visits depending on presentation of the subject.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721396] can be performed on day -1 of the visit at the investigator’s discretion.  
At-home pregnancy testing:  WOCBP will be provided with urine pregnancy tests for 
at-home testing prior to visits [ADDRESS_721397] for confirmation.  
14. PK and ADA samples are to be collected prior to study drug administration. In the event 
of suspected SAEs, such as anaphylaxis or hypersensitivity, additional samples for PK and 
ADA analyses may be collected as close to the event as practically possible.  
15. Refer to Section  9.2.11 . 
16. Genomic analysis is optional for all subjects enrolling in the study. One DNA sample is to 
be collected at the randomization visit, but if this sample collection was omitted a t baseline, 
it can be collected at any subsequent visit. Refer to Section  9.2.12 . 
9.1.2.  Early Termination Visit  
Subjects who are withdrawn from the study aft er randomization or at any time before the end of 
study visit will be asked to return to the study site for an early termination (ET) visit. Refer to 
Table  1 for assessments to be performed at an ET visit.  
9.1.3.  Unscheduled Visits  
All attempts should be made to keep subjects on the study schedule. Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follow -up of AEs,  or for any 
other reason, as warranted. Refer to Table  1 for assessments to be performed at unscheduled visits.  
9.2. Study Procedures  
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  
The following procedures will be performed primarily for determining study eligibility or 
characterizing the baseline population: medical history, demographics, and standard regional SPT . 
However, these assessments may also be performed at any unscheduled visit at the investigator’s 
discretion.  
9.2.2.  Pollen Counting  
Local pollen levels will be monitored throughout the study by [CONTACT_550068] a vendor. The 
start and the end of birch pollen season will be determined for each site using current standards for 
defining pollen seasons, factoring in local pollen counts from each site due to regional variability 
in pollen seasons (Pfaar, 2017 ). The start of the birch pollen season is defined as the first of 
3 consecutive days with a pollen count of 10 grains/m3 or greater. The end of the birch pollen 
season is defined as the last day of the last occurrence of 3 consecutive days with a pollen count 
of 10  grains/m3 or greater.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721398] and a regional SPT (such as with dust mites, grasses, other 
trees, including other birch homologous trees [such as alder  and oak], cat, and dog) will be 
performed to assess sensitization status. Skin prick test data may be used to determine the 
relationship between birch and regional alle rgen sensitization at baseline and pharmacodynamic 
effects of REGN5713 -[ADDRESS_721399] 3 mm greater than a negative control.  
For patients who enroll in the study, SPT will be performed as noted in Table  1 and the mean 
wheal diameters will be used to assess clinical responses to treatment. The allergens used for SPT 
will include birch pollen and 1 or 2 additional related homologous tree allergens.  
9.2.4.  Efficacy Procedures  
Efficacy measures will be assessed at time points indicated on Table  1. 
[IP_ADDRESS].  Total Nasal Symptom Score  
The TNSS ranges from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert 
scale ranging from 0 (none) to 3 (severe) for congestion, itching, an d rhinorrhea, and for sneezing. 
The TNSS will be recorded using an e -diary.  
[IP_ADDRESS].  Total Ocular Symptom Score  
The TOSS ranges from 0 to 6 and is based on 2 symptoms: itching/redness/gritty feeling and 
tearing/watering. Each of the 2 symptoms is graded 0 (absent),  1 (mild), 2 (moderate), or 
3 (severe). The TOSS will be recorded using an e -diary.  
[IP_ADDRESS].  Total Symptom Score  
The TSS is calculated by [CONTACT_550069], for a combined TSS of 0 to 18.  
[IP_ADDRESS].  Daily Medication Score  
Subjects will be asked to record thei r daily rescue medication use using an e -diary, including which 
medications and the amount of these pre -specified medications. This information will be used to 
calculate the DMS as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, 
olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone 
furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The maximum DMS score is 
20 (Calderon, 2014 ).  
[IP_ADDRESS].  Combined Symptom and Medication Score  
The CSMS is calculated by [CONTACT_550070], with scores ranging between 0 and 
38. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 44 
CONFIDENTIAL  [IP_ADDRESS].  Asthma Control Questionnaire  
The ACQ measures the adequacy of asthma control and change in asthma con trol that occurs 
spontaneously or as a result of treatment. The ACQ -[ADDRESS_721400] important to evaluate control: (1) awakening at night due 
to symptoms, (2) morning symptoms, (3) limit ation of daily activities, (4) shortness of breath, and 
(5) wheezing. The total score ranges from 0 to 6 with higher scores denoting less asthma control. 
A score of ≥1.5 is considered as uncontrolled asthma.  The ACQ -5 will be recorded using an 
e-diary.  
[IP_ADDRESS].  Standardized Rhinoconjunctivitis Quality of Life Questionnaire  
The RQLQ (S) has 28 questions in 7 domains: activity limitation, sleep problems, nose symptoms, 
eye symptoms, non -nose/eye symptoms, practical problems, and emotional function. There are 
[ADDRESS_721401] been by 
[CONTACT_550071] d to each question on a 7 -point scale 
(0 [not impaired at all] to 6 [severely impaired]). The overall RQLQ (S) score is the mean of all 
28 responses, and the individual domain scores are the means of the items in those domains 
(Juniper, 1991 ). The RQLQ (S) will be recorded using an e -diary.  
[IP_ADDRESS].  Pollen Food Allergy Symptom Questionnaire  
The PFASQ will be performed at time points according to  Table  1 to determine the types of food 
that produce an allergic reaction, the type of reaction, and how soon the reactions occur [adapted 
from (Geroldinger -Simic, 2011 )]. 
[IP_ADDRESS].  Patient Global Impression of Severity  
The PGI -S assesses the severity of se asonal allergy symptoms over the past 1 week. Symptom 
severity ranges from 0 (no symptoms), 1 (mild), 2 (moderate), and 3 (severe) symptoms.  
9.2.5.  Safety Procedures  
Safety measures will be assessed at time points indicated on Table  1.  
[IP_ADDRESS].  Vital Signs  
Vital signs include systolic and diastolic blood pressure, respi[INVESTIGATOR_12463]. Vital signs 
will be collected in a seated position. On the day of study drug administration, vital signs are taken 
prior to PK blood draw, prior to study drug admin istration, and at 2 hours (±10 min) after 
completion of the injection.  
[IP_ADDRESS].  Physical Examination  
A complete physical examination will be performed according to  Table  1. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 45 
CONFIDENTIAL  [IP_ADDRESS].  Body Weight  
Body weight will be assessed using calibrated scales. Subjects should remove shoes during weight 
assessments. Body weight will be recorded to the nearest 0.1 kg.  
[IP_ADDRESS].  Spi[INVESTIGATOR_260366] (American Thoracic Society [ATS]/European Respi[INVESTIGATOR_3764] [ERS] -compliant) 
as adjudicated by [CONTACT_6962], including measurements of forced vital capacity (FVC [L]), 
forced expi[INVESTIGATOR_12194] (FEV 1 [L]), FEV 1/FVC (%), peak expi[INVESTIGATOR_10229] (L/s), forced 
expi[INVESTIGATOR_10229] 25 to 75 (L/s), w ill be performed during screening and randomization to exclude 
any subjects with abnormal lung function and/or poorly controlled asthma.  
9.2.6.  Electrocardiogram  
A standard 12 -lead ECG will be performed at time points according to according to Table  1. Heart 
rate will be recorded from the ventricular rate and the PR, QRS, and QT intervals will be recorded. 
The ECG strips or reports will be retained with the sour ce documentation.  
To minimize variability, it is important that the patient be in a resting position for ≥10 minutes 
prior to the ECG evaluation. Body position should be consistently maintained for each ECG to 
prevent changes in heart rate.  
9.2.7.  Laboratory Tes ting 
[IP_ADDRESS].  Hematology, Blood Chemistry, Pregnancy Test, and Urinalysis  
Hematology, chemistry, pregnancy test, and urinalysis will be analyzed by a central laboratory. 
Detailed instructions for blood sample collection are in the laboratory manual provided to stud y 
sites.  
Samples for laboratory testing will be collected at visits according to Table  1. Tests will include:  
Blood chemistry  
Sodium  Total protein, seru m Total bilirubin  
Potassium  Creatinine  Triglycerides  
Chloride  Blood urea nitrogen (BUN)  Uric acid  
Carbon dioxide  Aspartate aminotransferase (AST)   
Calcium  Alanine aminotransferase (ALT)   
Glucose  Alkaline phosphatase   
Albumin    
Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721402]  
Other laboratory tests  
Subjects will be tested for FSH levels (postmenopausal women only) and will undergo serum and 
urine pregnancy testing (WOCBP only); pregnancy testing is not required of women confirmed 
postmenopausal. If any urine pregnancy test is positive, the site must perform a serum pregnancy 
test for confirmation. If a serum pregnancy test must be performed, study drug cannot be 
administered unless the serum pregnancy test is negative.  
Samples will be collected for quantitative assessment of total and allergen -specif ic IgE and will 
be analyzed by a central laboratory.  
Abnormal laboratory values and laboratory adverse events  
All laboratory values must be reviewed by [CONTACT_31594].  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality. When necessary, appropriate ancillary investigations 
should be initiated. If the abnormality fails to resolve or c annot be explained by [CONTACT_25037], the Medical/Study Director must 
be consulted.  
The clinical significance of an abnormal test value, within the context of the disease under study, 
must be d etermined by [CONTACT_093].  
Criteria for reporting laboratory values as an AE are provided in Section  10.1.1 . 
[IP_ADDRESS].  Serum Antibodies  
Levels of anti -birch pollen sIgE and anti -Bet v [ADDRESS_721403] regional allergens and common perennial allergens will be 
measured according to Table  1 to assess sensitization status to other common allergens and to 
evaluate the relationship between response to REGN5713 -5714 -5715 and poly/mono -sensitization 
(Van Ree, 1999 ). 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 47 
CONFIDENTIAL  Additional subclasses of serum antibodies (eg, IgG and IgG4 against birch pollen and Bet v 1) will 
be measured at screening. These results will be part of exploratory research analysis and will be 
included  in an exploratory biomarker report.  
9.2.8.  Drug Concentration and Measurements  
Samples for drug concentration measurement will be collected at visits listed in Table  1.  
Any unused samples may be used for exploratory research.  
9.2.9.  Immunogenicity Measurements and Samples  
Samples for ADA assessment for REGN5713, REGN5714 and REGN5715 will be collected at 
time points listed in Table  1. Anti -REGN5713, REGN5714, and REGN5715 neutralizing 
antibodies (NAb) analysis may be performed on ADA -positive serum samples. The overall 
immunogenicity risk will be taken into consid eration to assess the need for NAb analysis. Serum 
samples will be banked, if NAb analysis is to be conducted at a later time.  
Any unused samples may be used for exploratory research.  
9.2.10.  Pharmacodynamic and Exploratory Biomarker Procedures  
Blood samples will be obtained for additional exploratory research to better understand the effects 
of various anti -Bet v 1 antibodies on birch allergy. This will include the assessment of effective 
competition between REGN5713, REGN5714, and REGN5715 (eit her alone or in combination) 
and endogenous sIgE in serum for allergen binding in an in vitro interference/ inhibition assay.  
These results will be part of exploratory research analysis and will be included in an exploratory 
biomarker report, which will n ot be described in the clinical study report .  
[IP_ADDRESS].  Exploratory Biomarker Research  
Blood samples will be obtained for additional exploratory research to better understand the effects 
of various anti -Bet v 1 antibodies on birch allergy. This will include the ass essment of effective 
competition between REGN5713, REGN5714, REGN5715 (either alone or in combination), and 
endogenous serum IgE for allergen binding in an in -vitro interference/ inhibition assay.  
Additional blood samples will be collected for measuring s ubclasses of serum antibodies (eg, IgG 
and IgG4 against birch pollen and Bet v 1) at screening.  
Exploratory biomarker results not required for protocol -defined endpoint analyses will not be 
reported in the CSR. These results will be included in an explora tory biomarker report.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 48 
CONFIDENTIAL  9.2.11.  Future Biomedical Research (Optional)  
Subjects who agree to participate in the future biomedical research (FBR) sub -study will be 
required to consent to this optional sub -study before samples are banked for FBR. Additional 
samples wi ll be collected for FBR. Residual biomarker samples for study -related research, as well 
as unused PK and ADA samples, will be stored for up to 15 years after the final date of the database 
lock (or for a shorter time period if required per regio nal laws and regulations). The samples may 
be utilized for FBR that may or may not be directly related to the study, including being used as 
reference samples and assay development or validation. The results of these future biomedical 
research analyses wil l not be presented in the CSR.  
9.2.12.  Pharmacogenomic Analysis (Optional)  
Subjects who agree to participate in the genomics sub -study will be required to consent to this 
optional sub -study before collection of the samples. Whole blood samples for DNA extraction 
should be collected on day 1/baseline (predose) but can be collected at a later study visit. DNA 
sample will be collected for pharmacogenomics analyses to understand the genetic determinants 
of efficacy and safety associated with the treatments in this stud y and the molecular basis of birch 
allergy and related diseases. These samples will be single -coded as defined by [CONTACT_329125] (ICH) guideline E15. Samples will be stored for up to 15 years after 
the final date of the databas e lock (or for a shorter time period if required per regional laws and 
regulations). If there are specific site or country requirements involving the pharmacogenomic 
analyses which the Sponsor is unable to comply with, samples will not be collected at thos e sites.  
The purpose of the pharmacogenomic analyses is to identify genomic associations with clinical or 
biomarker response to REGN5713 -[ADDRESS_721404] of methods may be expanded to include novel methodology that may be developed during 
the course of this study or sample storage period. Results from the genomic analyses will not be 
reported in the CSR.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721405] all clinical events occurring during the study data 
collection , from the time of signing the ICF to the end  of on -treatment period (see  
Section  [IP_ADDRESS] ). Medical conditions that existed or were diagnosed prior to the signing of the 
informed consent will be re corded as part of medical history. Abnormal laboratory values and vital 
signs observed at the time of informed consent should also be recorded as medical history. Any 
subsequent worsening (ie, any clinically significant change in frequency and/or intensity ) of a pre -
existing condition that is temporally associated with the use of the study drug should also be 
recorded as an AE.  
At each visit, the investigator will determine whether any AEs have occurred by [CONTACT_46922]. Adverse events may be direc tly observed, reported spontaneously by [CONTACT_423], or by 
[CONTACT_550072]. Subjects should be questioned in a general way, without 
asking about the occurrence of any specific symptoms. The investigator must assess all AEs to 
determine seriousness, severity, and causality, in accordance with the definitions in Section  10.2. 
The investigator’s assessment must be clearly documented in the site’s source documentation with 
the investigator’s signature. The investigator should follow up on SAEs (and AESIs) until the y 
have resolved or are considered clinically stable; AEs should be followed until they are resolved 
or last study visit, whichever comes first.  
Always report the diagnosis as the AE or SAE term. When a diagnosis is unavailable, report the 
primary sign or s ymptom as the AE or SAE term with additional details included in the narrative 
until the diagnosis becomes available. If the signs and symptoms are distinct and do not suggest a 
common diagnosis, report them as individual entries of AE or SAE.  
Laboratory results, vital signs, and other diagnostic result s or findings  should be appraised by [CONTACT_173901].  Isolated abnormal laboratory results, vital sign 
findings, or other diagnostic findings (ie, not part of a repo rted diagnosis) should be reported as 
AEs if they are symptomatic, lead to study drug discontinuation,  dose reduction,  require corrective 
treatment, or constitute an AE in the investigator ’s clinical judgment . 
For events that are serious due to hospi[INVESTIGATOR_12191], the reason for hospi[INVESTIGATOR_31558] (diagnosis or symptom requiring hospi[INVESTIGATOR_059]). A procedure is not 
an AE or SAE, but the reason for the procedure may be an AE or SAE. Pre -planned (prior to 
signing the in formed consent form) procedure s, treatment s requiring hospi[INVESTIGATOR_31559]-existing conditions that do not worsen in severity, and admission for palliative or social care 
should not be reported as SAEs (see Section  10.2 for Definitions).  
For deaths, the underlying or immediate cause of death should always be reported as an SAE.  
Any SAE that may occur subsequent to the reporting period (end of the  on-treatment period) that 
the investigator assesses as related to study drug should also be reported.  
All AEs, SAEs, AESIs, and pregnancy reports are to be reported according to the procedures in 
Section  10.1.2  and Section  10.1.3 . 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 50 
CONFIDENTIAL  10.1.2.  Reporting Procedure  
All events (serious and non -serious) must be reported with investigator’s assessment of the event’s 
seriousness, severity, and causality to the blinded study drug. For SAEs and AESIs, a detailed 
narrative summarizing the course of the event, including its evaluation, treatment, and outcome 
should be provided on the AE CRF. Specific or estimated dates of event onset, treatment, and 
resolution should be included, when available. Medical history, concomitant medications, and 
laboratory data that are relevant to the event should also be summarized in the narrative. For fatal 
events, the narrative should state whether an autopsy was or will be performed and include the 
results if available. Information not available at the time of the initial report must be documented 
in a follow -up report. Source documents  (including hospi[INVESTIGATOR_24925], diagnostic reports, 
etc) will be summarized in the narrative on the AE CRF and retained at the  study center and 
available upon request.  
Urgent safety queries must be followed up and addressed promptly. Follow -up in formation and 
response to non -urgent safety queries should be combined for reporting to provide the most 
complete data possible within each follow -up.  
10.1.3.  Events that Require Expedited Reporting to Sponsor  
The following events also require reporting to the Sp onsor (or designee) within 24 hours of 
learning of the event:  
• SAEs  
• Selected Adverse Events of Special Interest (AESI; serious and nonserious) : Adverse 
events of special interest for this study include systemic or severe hypersensitivity 
reactions and sever e injection site reactions.  
• Pregnancy:  Although pregnancy is not considered an AE, it is the responsibility of the 
investigator to report to the Sponsor (or designee), within [ADDRESS_721406], and/or fetus and/or 
newborn th at meets the SAE criteria must be reported as an SAE. Outcome for all 
pregnancies should be reported to the Sponsor . 
10.2. Definitions  
10.2.1.  Adverse Event  
An AE is any untoward medical occurrence in a subject administered a study drug which may or 
may not have a causa l relationship with the study drug. Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease which is temporally 
associated with the use of a study drug, whether or not considered related to the s tudy drug 
(ICH  E2A Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994).  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721407] medical occurrence that at any dose:  
• Results in death  – includes all deaths, even thos e that appear to be completely unrelated 
to study drug (eg, a car accident in which a subject is a passenger).  
• Is life-threatening  – in the view of the investigator, the subject is at immediate risk of 
death at the time of the event. This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
• Requires in -patient hospi[INVESTIGATOR_869] . 
In-patient hospi[INVESTIGATOR_31561] a hospi[INVESTIGATOR_063] (any duration) or an 
emergency room visit for longer than 24 hours. Prolongation of existing hospi[INVESTIGATOR_24928] a hospi[INVESTIGATOR_50401] a new AE as determined by [CONTACT_550073].  
• Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).  
• Is a congenital anomaly/birth defect  
• Is an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_550029] 
(eg, intensive treatment in an eme rgency room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of 
drug dependency or drug abuse).  
Criteria for reporting SAEs must be followed for these events.  
10.2.3.  Adverse Events of Spe cial Interest  
An adverse event of special interest (AESI; serious or non -serious) is one of scientific and medical 
interest specific to the Sponsor’s product or program, for which ongoing monitoring and rapid 
communication by [CONTACT_550074] r can be appropriate. Such an event might warrant 
further investigation in order to characterize and understand it.  
10.2.4.  Severity  
The severity of AEs will be graded according to the following scale:  
• Mild:  Does not interfere in a significant manner with the sub ject normal functioning 
level. It may be an annoyance. Prescription drugs are not ordinarily needed for relief of 
symptoms, but may be given because of personality of the subject  
• Moderate:  Produces some impairment of functioning but is not hazardous to hea lth. It 
is uncomfortable or an embarrassment. Treatment for symptom may be needed  
• Severe:  Produces significant impairment of functioning or incapacitation and is a 
definite hazard to the subject’s health. Treatment for symptom may be given and/or 
subject h ospi[INVESTIGATOR_405467]-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 52 
CONFIDENTIAL  If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the value indicates.  
Injection site reactions  
The severity of injection site reactions will be graded according to the following s cale (semi -colon 
indicates “or” within description of grade):  
• Mild : Pain that does not interfere with activity; mild discomfort to touch; <5 cm of 
erythema or induration that does not interfere with activity  
• Moderate : Pain that requires repeated use of non -narcotic pain reliever >24 hours or 
interferes with activity; discomfort with movement; 5.1 cm to 10 cm erythema or 
induration or induration that interferes with activity  
• Severe : Pain that requires any use of narcotic pain reliever or that prevents daily 
activity; significant discomfort at rest; >10 cm erythema or induration; prevents daily 
activity; requires ER visit or hospi[INVESTIGATOR_059]; necrosis or exfoliative dermatitis  
10.2.5.  Causality  
The investigator must provide causality assessment as whether or not there is a reasonable 
possibility that the drug caused the adverse event, based on evidence or facts, his/her clinical 
judgment, and the following definitions. The causality assessment must  be made based on the 
available information and can be updated as new inf ormation becomes available.  
The following factors should be considered when assessing causality:  
• Temporal relationship: time to onset vs time drug was administered  
• Nature of the reactions: immediate versus long term  
• Clinical and pathological features of th e events  
• Existing information about the drug & same class of drugs  
• Concomitant medications  
• Underlying and concurrent illnesses  
• Response to dechallenge (drug discontinuation) or dose reduction  
• Subject’s medical and social history  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 53 
CONFIDENTIAL  Causality to the study drug (including study drug administration):  
• Related:  
− The AE follows a reasonable temporal sequence from study drug administration 
and cannot be reasonably explained by [CONTACT_25045], subject’s clinical 
(eg, disease under study, concurren t diseases, concomitant medications), or other 
external factors.  
or 
− The AE follows a reasonable temporal sequence from study drug administration 
and is a known reaction to the drug under study or its class of drugs or is predicted 
by [CONTACT_25046].  
• Not Related:  
− The AE does not follow a reasonable sequence from study drug administration or 
can be reasonably explained by [CONTACT_25045], subject’s clinical state 
(eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
Causality to the study conduct (protocol specified procedure):  
• Related:  
− The AE follows a reasonable temporal sequence from a protocol specified 
procedure and cannot be reasonably explained by [CONTACT_25045], 
subject’s cli nical (eg, disease under study, concurrent diseases, concomitant 
medications), or other external factors.  
• Not Related:  
− The AE does not follow a reasonable sequence from a protocol specified procedure 
or can be reasonably explained by [CONTACT_550075], subject’s clinical state 
(eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
10.3. Safety Monitoring  
The investigator will monitor the safety of study subject at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP). Any questions or 
concerns should be discussed with the Sponsor in a timely fashion. The Sponsor will monitor the 
safety data from across all study sites. The Medical/Study Director wil l have primary responsibility 
for the emerging safety profile of the compound, but will be supported by [CONTACT_25047] 
(eg, Global Patient Safety; Biostatistics and Data Management). Safety monitoring will be 
performed on an ongoing basis (eg, individua l review of SAEs) and on a periodic cumulative 
aggregate basis.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721408], Ethics 
Committee, and Investigators  
During the study, the Sponsor and/or the contract research organization (CRO) will inform health 
authorities, IECs/IRBs, and the participating investigators of any S[LOCATION_003]Rs (Suspected Unexpected 
Serious Adverse Reactions) occurring in other study centers or other studies of the active study 
drug (REGN5713 -5714 -5715), as appropriate per local reporting re quirements. In addition, the 
Sponsor and/or CRO will comply with any additional local safety reporting requirements. All 
notifications to investigators will contain only blinded information.   
Upon receipt of the Sponsor’s notification of a S[LOCATION_003]R that occur red with the study drug, the 
investigator will inform the Institutional Review Board (IRB)/Ethics Committee (EC) unless 
delegated to the Sponsor.  
Event expectedness for study drug ( REGN5713 -5714 -5715 ) is assessed against the Reference 
Safety Information se ction of the Investigator’s Brochure that is effective for expedited safety 
reporting.  
At the completion of the study, the Sponsor will report all safety observations made during the 
conduct of the trial in the Clinical Study Report to health authorities a nd IECs/IRB as appropriate.  
11. STATISTICAL PLAN  
This section provides the basis for the statistical analysis plan (SAP) for the study. The SAP will 
be revised prior to the end of the study to accommodate amendments to the clinical study protocol 
and to make changes to adapt to unexpected issues in study execution and data that may affect the 
planned analyses. The final SAP will be issued before the first database lock.  
Endpoints are listed in Section  4. Analysis variables are listed in Section  5.  
11.1. Statistical Hypothesis  
For comparison of a single d ose of REGN5713 -5714 -5715 to placebo, the following hypothesis 
of the primary endpoint (average CSMS over birch pollen season) will be tested:  
• H0: There is no difference in CSMS, averaged over the duration of the birch pollen 
season, in subjects receiving REGN5713 -5714 -5715 and placebo.  
• H1: The CSMS, averaged over the duration of the birch pollen season, is statistically 
significant different in subjects receiving REGN5713 -[ADDRESS_721409] in a hierarchical procedure for primary efficacy and 
secondary endpoints at 2 -sided 5% significance level.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721410] differences between REGN5713 -5714 -5715 and placebo on the 
primary endpoint of the average CSMS during birc h pollen season. A sample size of 150 enrolled 
subjects per arm gives 90% power to detect a mean difference in average CSMS of 1.9 (30% 
reduction from placebo) in REGN5713 -5714 -5715 (mean CSMS = 4.4) and placebo (mean CSMS 
= 6.3), assuming a common standar d deviation in CSMS of 4.5. The minimum significant 
difference in CSMS is 1.14, or approximately an 18% reduction from placebo. This sample size 
calculation assumes a 20% drop out rate (30 subjects per arm) and a two -sample t -test with two -
sided alpha of 0 .05. Estimates of mean and variability of the CSMS are based on pooled estimates 
across several field studies for grass immunotherapy, and a 30% treatment effect relative to 
placebo is in line with what was observed in the phase 1b POC study for REGN5713 -5714-5715.  
11.3. Analysis Sets  
11.3.1.  Efficacy Analysis Sets  
The full analysis set (FAS) includes all randomized subjects who had at least 1 e -diary entry with 
symptoms or medication score recorded during the birch pollen season; it is based on the treatment 
allocated (as randomized). Efficacy endpoints will be analyzed using the FAS.  
The per protocol set (PPS) includes all subjects in the FAS except for those who are excluded due 
to specified important protocol violations. Final determination of the PPS will be made pr ior to the 
database lock and will be outlined in the SAP.  
11.3.2.  Safety Analysis Set  
The safety analysis set (SAF) includes all randomized subjects who received any study drug; it is 
based on the treatment received (as treated). Treatment compliance/administratio n and all clinical 
safety variables will be analyzed using the SAF.  
11.3.3.  Pharmacokinetic Analysis Set  
The PK analysis population includes all treated subjects  who received any study drug (safety 
population) and had at least [ADDRESS_721411] dose of the study drug. Subjects will be analyzed 
according to the treatment actually received.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 56 
CONFIDENTIAL  11.4. Statistical Methods  
For continuous variables, descriptive statistics will include the following information: the numb er 
of subjects reflected in the calculation (n), mean, standard deviation, Q1, median, Q3, minimum, 
and maximum.  
For categorical or ordinal data, frequencies and percentages will be displayed for each category.  
11.4.1.  Subject Disposition  
The following will be provided:  
• The total number of screened subjects: met the inclusion criteria regarding the target 
indication and signed the ICF  
• The total number of randomized subjects: received a randomization number  
• The total number of subjects who discontinued the study,  and the reasons for 
discontinuation  
• The total number of subjects who discontinued from study treatment, and the reasons 
for discontinuation  
• A listing of subjects treated but not randomized, subjects randomized but not treated, 
and subjects randomized but not treated as randomized  
• A listing of subjects prematurely discontinued from treatment, along with reasons for 
discontinuation  
11.4.2.  Demography and Baseline Characteristics  
Demographic and baseline characteristics will be summarized descriptively by [CONTACT_3148] g roup, 
and by [CONTACT_161476].  
11.4.3.  Efficacy Analyses  
[IP_ADDRESS].  Primary Efficacy Analysis  
The efficacy endpoints will be analyzed using the FAS defined in Section  11.3.[ADDRESS_721412] model, with the 
treatment group and randomization stratification factors (as described in Section  8.5) as fixed 
effects and pollen  region as a random effect, to account for potential differences in birch pollen 
seasons based on the geographical location of each pollen region. Clinical sites will be pooled into 
different pollen regions which will be specified in the SAP. Subjects with  at least [ADDRESS_721413] with symptom and medical score (SMS) will be included. The CSMS will 
be calculated on all available data during the birch pollen season. The primary analysis will be 
based on the available values of daily sympt om score and daily medication score to calculate the 
average CSMS and no imputation will be needed for the primary endpoint during the birch pollen 
season.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 57 
CONFIDENTIAL  The average CSMS will be calculated based on daily symptom score (TNSS and TOSS, max of 
18/day) and  daily medication score (max of 20/day) recorded over the duration of the birch pollen 
season. The start and end of the birch pollen season will be defined for each site based on the local 
birch pollen counts. Only days with observed data (including any av ailable data of daily entries 
prior to subject discontinuation) will be included in the calculation of the average CSMS.  
Any rescue medication use will not be set to missing for the CSMS, but relevant prohibited 
medications (as listed in Section  8.9.1 ) that may have a long -term impact on symptom 
measurements will result in subsequent symptoms and medication scores to not be utilized in the 
CSMS for that  subject for a specified period of time (determined by [CONTACT_47661]). Relevant 
prohibited medications and corresponding time frames for censoring will be specified in the SAP.  
In addition, as a supportive analysis, a non -parametric analysis using the Wi lcoxon rank -sum test 
will be compared 2 group median in term of risk reduction from placebo for the primary endpoint 
of the average CSMS during the birch pollen season between REGN5713 -5714 -5715 and placebo. 
The Hodges -Lehmann estimator of median treatment  difference for 95% confidence interval will 
be provided. With respect to the missing data handling of daily entries, sensitivity analyses may 
be performed to evaluate the robustness of the conclusion drawn b ased on the main model for 
primary analysis cons idering a minimum number of daily entries during the birch pollen season. 
Details of the sensitivity analyses will be provided in the SAP.  
Subgroup analysis (eg, by [CONTACT_550076] -birch pollen IgE level <17.5 kUa/L versus ≥17.5 kUa/L) 
may also be performed.   
[IP_ADDRESS].  Secondary Efficacy Analysis  
The average daily TNSS, TSS, TOSS, and DMS during the birch pollen season will be analyzed 
in the same fashion as the primary analysis for the subjects receiving REGN5713 -[ADDRESS_721414] will be included in the 
analysis, and only days with observed data (including any available data of daily entries prior to 
subject discontinuation) will be included in the calculation of average score.  
[IP_ADDRESS].  Exploratory Efficacy Ana lysis 
Exploratory efficacy endpoints, including the average ACQ -5, RQLQ (S), and PGI -S scores during 
the birch pollen season will be analyzed in the same fashion as the primary analysis for the subjects 
receiving REGN5713 -[ADDRESS_721415] 1 day of data will be 
included in the analysis.  
11.4.4.  Control of Multiplicity  
Type I error rate will be controlled using a hierarchical testing strategy for the primary and key 
secondary endpoints at the 2 -sided significant level of 0.05. The hier archical order of the primary 
and key secondary endpoints will be specified in the SAP.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 58 
CONFIDENTIAL  11.4.5.  Safety Analysis  
[IP_ADDRESS].  Adverse Events  
Definitions  
For safety variables, 2 observation periods are defined:  
• The pre -treatment period is defined as the time from signing the ICF  to before the first 
dose of study drug.  
• The on -treatment period is defined as the day from first dose of study drug to the end 
of study visit . 
Treatment -emergent adverse events are defined as those that are not present at baseline or represent 
the exacerb ation of a pre -existing condition during the on -treatment period.  
Analysis  
All AEs reported in this study will be coded using the currently available version of the Medical 
Dictionary for Regulatory Activities (MedDRA®). Coding will be to lowest level terms. The 
preferred term (PT), and the primary system organ class (SOC) will be listed.  
Summaries of all TEAEs by [CONTACT_12919]:  
• The number (n) and percentage (%) of subjects with at least 1 TEAE by [CONTACT_3592]  
• TEAEs by [CONTACT_926] (according t o the grading scale outlined in Section  10.2.4 ), 
presented by [CONTACT_3592]  
• TEAEs by [CONTACT_72843] (related, not related), presented by [CONTACT_1198]  
• Treatment -emergent AESIs (defined with a PT or a prespecified groupi[INVESTIGATOR_007])  
Deaths and other SAEs will be listed and summarized by [CONTACT_1570].  
Treatment -emergent adverse events leading to permanent treatment discontinuation will be listed 
and summ arized by [CONTACT_1570].  
[IP_ADDRESS].  Other Safety  
Vital signs  
Vital signs (eg, pulse, blood pressure, and respi[INVESTIGATOR_1487]) will be summarized by [CONTACT_151351].  
Laboratory tests  
Labora tory test results will be summarized by [CONTACT_25052].  
Number and percentage of subjects with a potentially clinically significant value (PCSV) at any 
post-randomization time  point will be summarized for each clinical laboratory test for all subjects 
and separately for subjects in whom the PCSV criterion was normal or missing at baseline.  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods m ay be 
used to present the results for laboratory tests of interest.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 59 
CONFIDENTIAL  Listings will be provided with flags indicating the out of laboratory range values.  
[IP_ADDRESS].  Treatment Exposure  
This is a single dose study.  
[IP_ADDRESS].  Treatment Compliance  
Treatment compliance will be assess ed via the summary of treatment exposure as described in 
Section  [IP_ADDRESS] . 
11.4.6.  Pharmacokinetics  
[IP_ADDRESS].  Analysis of Drug Concentration Data  
The concentrations of total REGN5713, REGN5714, and REGN5715 over time will be 
summarized by [CONTACT_550077].  
No formal statistical hypothesis testing will be performed.  
11.4.7.  Analysis of Immunogenicity Data  
Immunogenicity will be characterized by [CONTACT_550078]:  
• Pre-existing immunoreactivity, defined as a positive ADA assay response at baseline, 
with all post -dose ADA results negative, or a positive assay response at baseline, with 
all post-dose ADA assay responses less than 9 -fold over baseline titer levels  
• Treatment -emergent ADA response, defined as any post -dose positive ADA assay 
response when the baseline results are negative  
• Treatment boosted ADA response, defined as any post -dose positive ADA assay 
response that is 9 -fold over baseline titer levels when baseline is positive in the ADA 
assay  
• Maximum ADA Titer values  
− Low (titer <1,000)  
− Moderate (1,000≤ titer ≤10,000)  
− High (titer >10,000)  
Listings of pre -existing, treatment -boosted,  and treatment -emergent ADA responses, and ADA 
titers presented by [CONTACT_1130], time point, and treatment group will be provided separately for 
REGN5713, REGN5714, and REGN5715. Incidence of treatment -emergent ADA will be assessed 
as absolute occurrence (N) an d percent of subjects (%), grouped by [CONTACT_550079].  
Plots of drug concentrations will be examined and the influence of ADA responses on individual 
PK profiles evaluated separately for REGN5713, REGN5714, and REGN5715. Assessment of 
impact of ADA responses on safety and efficacy may be provided.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721416] mean wheal diameters 
will be analyzed using an analysis of co variance (ANCOVA) model, with treatment, 
randomization stratification factors, visit and the treatment by [CONTACT_550080] a covariate. Between group estimates comparing 
REGN5713 -[ADDRESS_721417] variability in sIgE in and out of 
birch pollen season will also be evaluated.  
11.5. Additional Statistical Data Handli ng Conventions  
The following analysis and data conventions will be followed:  
Definition of baseline  
The last assessment before the administration of study drug on day [ADDRESS_721418] occurred on or after the intake of study medication, except if an incomplete date (eg, month 
and year) clearly indicates that the event started prior to treatment. If the partial date indicates the 
same month or year of the intake of study medication date, then the start date by [CONTACT_550081]; otherwise, the missing day or month by [CONTACT_550082].  
No imputations for missing laboratory data, ECG data, vital sign data, or physical examination 
data will be made.  
Visit windows  
Assessments taken outside of protocol -allowable windows will be displayed according to the case 
report form (CRF) assessment recorded by [CONTACT_093].  
Unscheduled asses sments  
Extra assessments (laboratory data or vital signs associated with non -protocol clinical visits or 
obtained in the course of investigating or managing AEs) will be included in listings, but not 
summaries. If more than [ADDRESS_721419] observation will 
be used in summaries and all observations will be presented in listings.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 61 
CONFIDENTIAL  11.6. Interim Analysis  
No formal interim analysis will be conducted.  
11.7. Statistical Considerations Surrounding the Premature Termination 
of a Stu dy  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and Sponsor 
responsibilities surrounding the premature termination of a study  are presented in Section  15.1. 
12. QUALITY CONTROL AND QUALITY ASSURANCE  
In accordance with ICH E6, the Sponsor is responsible for quality assurance to ensure that the 
study is conducted and the data generated, recorded, and reported in compliance with the protocol, 
GCP, and any applicable regulatory requirement(s). The planned  quality assurance and quality 
control procedures for the study are described in this section.  
12.1. Data Management and Electronic Systems  
12.1.1.  Data Management  
A data management plan specifying all relevant aspects of data processing for the study (including 
data v alidation [quality -checking], cleaning, correcting, releasing) will be maintained and stored 
at Regeneron (Sponsor).  
A medical coding plan will specify the processes and the dictionary used for coding. All data 
coding (eg, AEs, baseline findings, medicatio n, medical history) will be done using internationally 
recognized and accepted dictionaries.  
The CRF data for this study will be collected with an electronic data capture (EDC) system, 
Medidata Rave.  
12.1.2.  Electronic Systems  
Electronic systems that may be used t o process and/or collect data in this study will include the 
following:  
• IVRS/IWRS system – randomization, study drug supply  
• EDC system – data capture  – Medidata Rave  
• Statistical Analysis System (SAS) – statistical review and analysis  
• Pharmacovigilance safe ty database  
• Electronic diary and tablet for collection of patient -reported outcomes data  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 62 
CONFIDENTIAL  12.2. Study Monitoring  
12.2.1.  Monitoring of Study Sites  
Regeneron uses a study -specific risk-based approach to study monitoring and oversight, aligned 
with risk-based quality prin ciples, outlined in ICH E6 (R2) Guideline for Good Clinical Practice. 
Risk-Based Quality Monitoring (RBQM) methodology focuses on employing a fit -for-purpose 
monitoring strategy, supported either directly by [CONTACT_550083], or via our CRO partners. 
RBQM strategies include: reduced source data verification (SDV), targeted source data review 
(SDR), the use of off -site/remote and triggered on -site monitoring visits, and Centralized 
Monitoring to identify site level risks and study level trends. The inves tigator must allow study -
related monitoring activities to occur.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by [CONTACT_1191], complete, and verifiable from source documents, 
that the safety and rights of subjects are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
12.2.2.  Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate subject records (source 
documents). The site is responsible to ensure quality within their records and systems and are 
accountable for ensuring that all source data and C RF data are timely, accurate and complete.  
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an electronic CRF). Case report forms and source documents 
must be available at a ll times for inspection by [CONTACT_550084].  
12.2.3.  Case Report Form Requirements  
Study data obtained in the course of the clinical study will be recorded on electronic Case Report 
Forms (CRFs) within the EDC sy stem by [CONTACT_1146]. All required CRFs must be 
completed for each and every subject enrolled in the study. The investigator must ensure the 
accuracy, completeness, and timeliness of the data reported to the Sponsor in the CRFs. After 
review of t he clinical data for each subject, the investigator must provide an electronic signature. 
A copy of each subject CRF casebook is to be retained by [CONTACT_550085].  
Corrections to the CRF  will be entered in the CRF by [CONTACT_31612].  
All changes, including date and person performing corrections, will be available via the audit trail , 
which is part of the EDC system.  For corrections made via data queries, a reason for any alteration 
must be provided.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721420] to a quality assurance audit or inspection by [CONTACT_550086]. S hould this occur, the investigator is responsible for:  
• Informing the Sponsor of a planned inspection by [CONTACT_50482], and authorizing the Sponsor’s participation in the inspection  
• Providing access to all necessary facilities, study data, and documents for the inspection 
or audit  
• Communicating any information arising from inspection by [CONTACT_103274]  
• Taking all appropriate measures requested by [CONTACT_550087] s 
found during the audit or inspection  
Documents subject to audit or inspection include but are not limited to all source documents, CRFs, 
medical records, correspondence, ICFs, IRB/EC files, documentation of certification and quality 
control of supporting  laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities. Conditions of study material storage are also subject to inspection. In addition, 
representatives of the Sponsor may observe the conduct of any aspect of the  clinical study or its 
supporting activities both within and outside of the investigator's institution.  
In all instances, the confidentiality of the data must be respected.  
12.4. Study Documentation  
12.4.1.  Certification of Accuracy of Data  
A declaration assuring the ac curacy and content of the data recorded on the eCRF must be signed 
electronically by [CONTACT_093]. This signed declaration accompanies each set of subject final 
eCRF that will be provided to the Sponsor.  
12.4.2.  Retention of Records  
The investigator must retai n all essential study documents, including ICFs, source documents, 
investigator copi[INVESTIGATOR_3110], and drug accountability records for at least [ADDRESS_721421] be destroyed in a manner that ensures confidentiality.  
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the Sponsor (written notification) and the relevant records will be 
transferred to a mutually a greed -upon destination.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 64 
CONFIDENTIAL  13. ETHICAL AND REGULATO RY CONSIDERATIONS   
13.1. Good Clinical Practice Statement  
It is the responsibility of both the Sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical princ iples that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements.  
13.2. Informed Consent  
The principles of informed consent are described in ICH guidelines for GCP.  
The IC F used by [CONTACT_103277]/EC. A copy of the IRB/EC -approved ICF and documentation 
of approval must be provided to the Sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee (if acceptable by [CONTACT_427]) to obtain 
written informed consent from each subject prior to his/her participation in the study and after the 
aims, methods, objectives, and potentia l hazards of the study have been explained to the subject in 
language that he/she can understand. The ICF should be signed and dated by [CONTACT_550088].  
• Subjects  who can write but cannot read will have the ICF read to them before signing 
and dating the ICF.  
• Subjects who can understand but who can neither write nor read will have the ICF read 
to them in presence of an impartial witness, who will sign and date the I CF to confirm 
that informed consent was given.  
The original ICF must be retained by [CONTACT_86211]'s study record, and a 
copy of the signed ICF must be given to the subject.  
If new safety information results in significant changes in the risk/benefit assessment, or if there 
are significant changes to the study procedures, the ICF must be reviewed and updated 
appropriately. All study subjects must be informed of the new information and provide their 
written consent if they wish to co ntinue in the study. The original signed revised ICF must be 
maintained in the subject’s study record and a copy must be given to the subject.  
13.3. Subjects Confidentiality and Data Protection  
The investigator must take all appropriate measures to ensure that t he anonymity of each study 
subject will be maintained. Subjects should be identified by a subject identification number only, 
on CRFs or other documents submitted to the Sponsor. Documents that will not be submitted to 
the Sponsor (eg, signed ICF) must be kept in strict confidence.  
The subject 's and investigator's personal data, which may be included in the Sponsor database, 
will be treated in compliance with all applicable laws and regulations. The Sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by [CONTACT_13159].  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721422] and Ethics Committee  
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve:  
• The protocol, ICF, and any other material s to be provided to the subjects 
(eg, advertising) before any subject may be enrolled in the study  
• Any amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the subj ect, in which 
case the IRB/EC should be informed as soon as possible  
• Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of subjects or 
the continued conduct of the clinical study.  
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions 
must be received by [CONTACT_103278]. The 
approval letter shoul d include the study number and title, the documents reviewed, and the date of 
the review.  
Records of the IRB/EC review and approval of all study documents (including approval of ongoing 
studies) must be kept on file by [CONTACT_093].  
13.5. Clinical Study Data  Transparency  
Final study results will be published on a public clinical trial website according to applicable local 
guidelines and regulations. Treatment codes will be disseminated to each investigation site 
thereafter.  
14. PROTOCOL AMENDMENTS  
The Sponsor may  not implement a change in the design of the protocol or ICF without an 
IRB/EC  approved amendment. Where required per local legislation, regulatory authority approval 
will also be sought.  
15. PREMATURE TERMINATIO N OF THE STUDY OR 
CLOSE -OUT OF A SITE  
15.1. Premature  Termination of the Study  
The Sponsor has the right to terminate the study prematurely. Reasons may include efficacy, 
safety, or futility, among others. Should the Sponsor decide to terminate the study, the 
investigator(s) will be notified in writing.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721423] the right to close -out a site prematurely.  
Investigator’s Decision  
The investigator must notify the Sponsor of a desire to close -out a site in writing, providing at least 
30 days’ notice. The final decision should be made through mutual agreement with the Sponsor. 
Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The Sponsor will notify the investigator(s) of a decision to close -out a study site in writing. 
Reasons may include the following, among others:  
• The investigator has received all items and information necessary to perform the study, 
but has not enrolled a ny subject within a reasonable period of time  
• The investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulati ons, or breach of any applicable ICH 
guidelines  
• The total number of subjects required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirem ents, and adequate consideration must be given to the protection of 
the subjects’ interests.  
16. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
17. FINANCING AND INSURA NCE   
Financing and insurance information is provided as a s eparate agreement.  
18. PUBLICATION POLICY   
Publication rights and procedures will be outlined in a separate clinical study agreement.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 67 
CONFIDENTIAL  19. REFERENCES   
Asero R. Effects of birch pollen -specific immunotherapy on apple allergy in birch pollen -
hyperse nsitive patients. Clin Exp Allergy 1998; 28(11):1368 -73. 
Asero R. Effects of birch pollen SIT on apple allergy: a matter of dosage? Allergy 2004; 
59(12):[ADDRESS_721424]? Allergy  
2003; 58(5):[ADDRESS_721425] of pollen -specific sublingual immunotherapy on oral 
allergy syndrome: an observational study. World Allergy Organ J 2008; 1(5):79 -84. 
Biedermann T, Kuna P, Panzner P, Valovirta E, Andersson M, de  Blay F, et al. The SQ tree SLIT -
tablet is highly effective and well tolerated: Results from a randomized, double -blind, placebo -
controlled phase III trial. J Allergy Clin Immunol 2019a; 143(3):1058 -66.e6.  
Biedermann T, Winther L, Till SJ, Panzner P, Knuls t A, Valovirta E. Birch pollen allergy in 
Europe. Allergy 2019b; 74(7):[ADDRESS_721426], Tiemessen MM, Zuidmeer L, van Leeuwen A, Hoffmann -Sommergruber K, 
Bruijnzeel -Koomen CA, et al. Efficacy of birch -pollen immunotherapy on cross -reactive food 
allergy  confirmed by [CONTACT_550089] -blind food challenges. Clin Exp Allergy 2004; 
34(5):761 -9. 
Bousquet J, Lockey R, Malling HJ, Alvarez -Cuesta E, Canonica GW, Chapman MD, et al. 
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Hea lth Organization. 
American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 
81(5):[ADDRESS_721427] on Asthma (ARIA) guideli nes-2016 revision. J Allergy Clin Immunol 
2017; 140(4):[ADDRESS_721428] of tree pollen specific, subcutaneous 
immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004; 59(12):1272 -6. 
Burbach  GJ, Heinzerling LM, Edenharter G, Bachert C, Bindslev -Jensen C, Bonini S, et al. 
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. 
Allergy 2009; 64(10):[ADDRESS_721429] Rev 2007; 1:Cd001936.  
Calderon MA, Bernstein DI, Blaiss M, Andersen JS, Nolte H. A comparative analysis of symptom 
and medication scoring methods used i n clinical trials of sublingual immunotherapy for seasonal 
allergic rhinitis. Clin Exp Allergy 2014; 44(10):1228 -39. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 68 
CONFIDENTIAL  Canonica GW, Cox L, Pawankar R, Baena -Cagnani CE, Blaiss M, Bonini S, et al. Sublingual 
immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 
2014; 7(1):6.  
Chan -Yeung M, Anthonisen NR, Becklake MR, Bowie D, Sonia Buist A, Dimich -Ward H, et al. 
Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. 
Allergy 2010;  65(11):1404 -13. 
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a 
practice parameter third update. J Allergy Clin Immunol 2011; 127([ADDRESS_721430]):S1 -55. 
Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine -Tebb e J. Effective treatment 
of house dust mite -induced allergic rhinitis with 2 doses of the SQ HDM SLIT -tablet: Results from 
a randomized, double -blind, placebo -controlled phase III trial. J Allergy Clin Immunol 2016; 
137(2):444 -51.e8.  
Didier A, Worm M, Hora k F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3 -year 
efficacy of pre - and coseasonal 5 -grass -pollen sublingual immunotherapy tablets in patients with 
grass pollen -induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128(3):559 -66. 
Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long -term clinical 
efficacy in grass pollen -induced rhinoconjunctivitis after treatment with SQ -standardized grass 
allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125(1):131 -8.e1-7. 
Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ -standardized 
sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of 
treatment in a randomized trial. J Allergy Clin Immunol 2012; 129(3):717 -25.e5.  
Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J 
Allergy Clin Immunol 2016; 137(2):339 -49.e10.  
Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long -term clinical 
efficacy of grass -pollen immunotherapy. N Engl J Med 1999; 341(7):468 -75. 
Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, et al. Identification of 
allergens in fruits and vegetables: IgE cross -reactivities with the important birch pollen allergens 
Bet v 1 and Be t v 2 (birch profilin). J Allergy Clin Immunol 1995; 95(5 Pt 1):962 -9. 
Epstein TG, Calabria C, Cox LS, Dreborg S. Current Evidence on Safety and Practical 
Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United 
States. J  Allergy Clin Immunol Pract 2017; 5(1):34 -40.e2.  
Eriksson NE, Formgren H, Svenonius E. Food hypersensitivity in patients with pollen allergy. 
Allergy 1982; 37(6):437 -43. 
Erler A, Hawranek T, Kruckemeier L, Asam C, Egger M, Ferreira F, et al. Proteomic profiling of 
birch (Betula verrucosa) pollen extracts from different origins. Proteomics 2011; 11(8):1486 -98. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721431]. J Allergy 
Clin Immunol 2003; 111(1):155 -61. 
Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125([ADDRESS_721432] 2):S306 -13. 
Frew AJ. Immunotherapy: how safe is safe? Clin Exp Allergy 2006a; 36(3):[ADDRESS_721433] in treatment -resistant seasonal allergic 
rhinoconjunctivitis. J Allergy Clin Immunol 2006b; 117(2):[ADDRESS_721434] Team. Ann Allergy Asthma Immunol 1998; 81(3):203 -10. 
Geroldinger -Simic M, Zelniker T, Aberer W, Ebner C, Eg ger C, Greiderer A, et al. Birch pollen -
related food allergy: clinical aspects and the role of allergen -specific IgE and IgG4 antibodies. J 
Allergy Clin Immunol 2011; 127(3):616 -22.e1.  
Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independe nt risk factor for adult -
onset asthma. J Allergy Clin Immunol 2002; 109(3):419 -25. 
Guilbert A, Cox B, Bruffaerts N, Hoebeke L, Packeu A, Hendrickx M, et al. Relationships between 
aeroallergen levels and hospi[INVESTIGATOR_550030] -Capi[INVESTIGATOR_17399] l Region: a daily time 
series analysis. Environ Health 2018; 17(1):35.  
Halken S, Larenas -Linnemann D, Roberts G, Calderon MA, Angier E, Pfaar O, et al. EAACI 
guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 2017; 
28(8):[ADDRESS_721435] of hyposensitization for tree 
pollinosis on associated apple allergy. J Investig Allergol Clin Immunol 1995; 5(5):259 -67. 
Ito K, Weinberger KR, Robinson GS, Sheffield PE, Lall R, Mathes R,  et al. The associations 
between daily spring pollen counts, over -the-counter allergy medication sales, and asthma 
syndrome emergency department visits in [LOCATION_001] City, 2002 -2012. Environ Health 2015; 
14(71).  
James LK, Shamji MH, Walker SM, Wilson DR, Wac hholz PA, Francis JN, et al. Long -term 
tolerance after allergen immunotherapy is accompanied by [CONTACT_550090]. J Allergy Clin Immunol 2011; 127(2):509 -16 e1 -5. 
Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner  O, et al. IgE and IgG 
antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula 
verrucosa. Allergy 1989; 44(6):385 -95. 
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinica l 
trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21(1):77 -83. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 70 
CONFIDENTIAL  Kelso JM, Jones RT, Tellez R, Yunginger JW. Oral allergy syndrome successfully treated with 
pollen immunotherapy. Ann Allergy Asthma Immunol 1995; 74(5):391 -6. 
Lemberg ML, Berk T, Shah -Hosseini K, Kasche EM, Mosges R. Sublingual versus subcutaneous 
immunotherapy: patient adherence at a large German allergy center. Patient Prefer Adherence 
2017; 11(63 -70). 
Leynaert B, Neukirch F, Demoly P, Bousquet J. Epi[INVESTIGATOR_550031]. J Allergy Clin Immunol 2000; 106([ADDRESS_721436]):S201 -5. 
Lin RY, Clauss AE, Bennett ES. Hypersensitivity to common tree pollens in [LOCATION_001] City 
patients. Allergy Asthma Proc 2002; 23(4):253 -8. 
Makela MJ, Gyllfors P, Valovirta E, Steffensen MA, Gronager PM, Savolainen J, et al. 
Immunotherapy With the SQ Tree SLIT -tablet in Adults and Adolescents With Allergic 
Rhinoconjunctivitis. Clin Ther 2018; 40(4):574 -86.e4.  
Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of e fficacy, 
safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch 
pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007; 39(4):119 -22. 
Musa F, Al -Ahmad M, Arifhodzic N, Al -Herz W. Compliance with allergen immunothera py and 
factors affecting compliance among patients with respi[INVESTIGATOR_269463]. Hum Vaccin Immunother 
2017; 13(3):514 -7. 
Navarro A, Colas C, Anton E, Conde J, Davila I, Dordal MT, et al. Epi[INVESTIGATOR_550032]: A lergologica -2005. J Investig Allergol Clin Immunol 
2009; [ADDRESS_721437] 2(7 -13). 
Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin 
Immunol 2004; 113(4):635 -42. 
Niederberger V, Pauli G, Gronlund H, Froschl R, Rumpold H, Kraft  D, et al. Recombinant birch 
pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epi[INVESTIGATOR_550033], alder, 
hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different 
populations. J Allergy Clin Immuno l 1998; 102(4 Pt 1):[ADDRESS_721438] mite sublingual immunotherapy tablet in North American adolescents and adults in a 
randomized, placebo -controlled trial. J Allergy Clin Immunol 2016; 138(6):1631 -8. 
Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy with 
monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun 2018; 
9(1):1421.  
Pablos I, Wildner S , Asam C, Wallner M, Gadermaier G. Pollen Allergens for Molecular 
Diagnosis. Curr Allergy Asthma Rep 2016; 16(4):31.  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 71 
CONFIDENTIAL  Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch 
pollen vaccine for the treatment of birch -allergic rhinoconjunctivitis. J Allergy Clin Immunol 
2008; 122(5):951 -60. 
Pawankar R, Canonica GW, Casale T, RF L. The World Allergy Organization white book on 
allergy. In. Milwaukee: World Allergy Organization; 2011.  
Pfaar O, Calderon MA, Andrews CP, Ang jeli E, Bergmann KC, Bønløkke JH, et al. Allergen 
exposure chambers: harmonizing current concepts and projecting the needs for the future - an 
EAACI Position Paper. Allergy 2017; 72(7):1035 -42. 
Rosario N, Bielory L. Epi[INVESTIGATOR_550034].  Curr Opin Allergy Clin Immunol 
2011; 11(5):471 -6. 
Salo PM, Arbes SJ, Jr., Jaramillo R, Calatroni A, Weir CH, Sever ML, et al. Prevalence of allergic 
sensitization in the [LOCATION_002]: results from the National Health and Nutrition Examination 
Survey (NHA NES) 2005 -2006. J Allergy Clin Immunol 2014; 134(2):350 -9. 
Schenk MF, Cordewener JH, America AH, Peters J, Smulders MJ, Gilissen LJ. Proteomic analysis 
of the major birch allergen Bet v 1 predicts allergenicity for 15 birch species. J Proteomics 2011; 
74(8):1290 -300. 
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of 
asthma: a longitudinal population -based study. Lancet 2008; 372(9643):1049 -57. 
Sierra -Heredia C, North M, Brook J, Daly C, Ellis AK, Henderson D, et al. Aeroallergens in 
Canada: Distribution, Public Health Impacts, and Opportunities for Prevention. Int J Environ Res 
Public Health 2018; 15(8).  
Uermosi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, et al. Mechanisms of 
allergen -specific desens itization. J Allergy Clin Immunol 2010; 126(2):375 -83. 
Van Ree R, Van Leeuwen WA, Akkerdaas JH, Aalberse RC. How far can we simplify in vitro 
diagnostics for Fagales tree pollen allergy? A study with three whole pollen extracts and purified 
natural and rec ombinant allergens. Clin Exp Allergy 1999; 29(6):[ADDRESS_721439] of Rhinitis 
on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract 2018; 6(4):1274 -
86.e9.  
Vanek -Krebi tz M, Hoffmann -Sommergruber K, Laimer da Camara Machado M, Susani M, Ebner 
C, Kraft D, et al. Cloning and sequencing of Mal d 1, the major allergen from apple (Malus 
domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen . 
Biochem Biophys Res Commun 1995; 214(2):538 -51. 
Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real -world benefits of allergen 
immunotherapy for birch pollen -associated allergic rhinitis and asthma. Allergy 2019; 74(3):594 -
604. 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:[ADDRESS_721440], Durham SR. Grass pollen immunotherapy for 
seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 
107(1):87 -93. 
Wallace DV, Dykewicz MS. Seasonal Allergic Rhinitis: A focused systematic review and prac tice 
parameter update. Curr Opin Allergy Clin Immunol 2017a; 17(4):286 -94. 
Wallace DV, Dykewicz MS, Bernstein DI, Blessing -Moore J, Cox L, Khan DA, et al. The 
diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 
2008;  122([ADDRESS_721441]):S1 -84. 
Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic Treatment of 
Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice 
Parameters. Ann Intern Med 2017b; 167(12):[ADDRESS_721442] for allergic rhinitis: A 
systematic review and meta -analysis. Biomed Pharmacother 2016; 83(989 -97). 
 
 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 73 
CONFIDENTIAL  20. INVESTIGATOR’S AGREE MENT  
I have read the attached protocol: A PHASE [ADDRESS_721443] not be disclosed to 
anyone other than the recipi[INVESTIGATOR_14251]/EC. I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of the Sponsor.  
 
 
 
   
(Signature [CONTACT_7919])   (Date)  
   
(Printed Name)    
 
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Clinical Study Protocol   R5713 -5714 -5715 -ALG -2001 Original  
 
Regeneron Pharmaceuticals, Inc .  Page 74 
CONFIDENTIAL  SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the planned conduct of the study.  
Study Title:   A Phase 3 Randomized, Double -Blind, Placebo -Controlled Study Assessing the 
Efficacy of Anti -Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic 
Rhinitis  
Protocol Number:  R5713 -5714 -5715 -ALG -2001 
Protocol Version:  R5713 -5714 -5715 -ALG -2001 Original  
See appended electronic signature [CONTACT_25085]’s Responsible Medical/Study Director  
See appended electronic signature [CONTACT_25085]’s Responsible Regulatory Liaison  
See appended electronic signature [CONTACT_550092] e 
Sponsor’s Responsible Clinical Study Lead  
See appended electronic signature [CONTACT_25085]’s Responsible Biostatistician  
                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
Signature [CONTACT_11032]-RIM-00121234 v2.0
Signature [CONTACT_11032]-RIM-00121234 v2.0 ApprovedESig Approval
-2020 15:12:39 GMT[PHONE_006]
ESig Approval
20 15:13:57 GMT[PHONE_006]
ESig Approval
-2020 15:17:57 GMT[PHONE_006]
ESig Approval
00                                        VV-RIM-00121234-2.0 Approved - 28 Sep 2020 GMT-5:00
